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Proteinopathies are neurodegenerative disorders characterized by accumulation of specific 
misfolded or aggregated proteins in the nervous tissue. Some of the major proteinopathies include 
prions, Parkinson’s, Alzheimer’s, Huntington’s and dementia. Prion diseases are classical 
transmissible spongiform encephalopathies (TSEs) characterized by an always fatal, progressive 
neuronal degeneration in the brain due to infectious misfolded prion proteins. Chronic wasting 
disease (CWD) is a TSE affecting both wild and captive cervids, such as mule deer, white-tailed 
deer, elk and moose, with a prolonged incubation period. Hence, we attempted to use an 
ultrasensitive real-time quaking-induced conversion (RT-QuIC) assay to diagnose CWD using 
recto-anal mucosa-associated lymphoid tissue (RAMALT) from farmed white-tailed deer. We also 
employed the RT-QuIC assay with a neuronal cell culture model harboring RML scrapie prion and 
organotypic slice cultures to investigate how the divalent cation manganese (Mn), whose 
neurotoxicity has been linked to metal-binding proteins, promotes the aggregation of prion protein 
and the seeding activity of scrapie prion. Mn altered the aggregation propensity of prions in a linear 
relationship with the cell density when seeded with prion-infected cells but not for the uninfected 
cells. Our study unraveled a causal link for protein aggregation in prion proteinopathies by 
providing evidence of Mn binding to metal-binding domains of the prion protein. Mn can cause 
neurological, Parkinsonian-like symptoms in occupationally exposed individuals like welders who 
are chronically exposed to Mn-rich welding fumes. No blood-based biomarkers are available for 
Mn poisoning in humans except for expensive imaging techniques, like brain MRI. Hence, we 
used the RT-QuIC assay to detect α-synuclein (αSyn) aggregates present in exosomes isolated 
from a blinded cohort of serum and plasma samples from a welding fume-exposed population and 
age-matched controls. Using the RT-QuIC assay, we differentiated welders from controls with 
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>95% sensitivity and specificity, suggesting that exosomal αSyn aggregates may serve as a 
circulating biomarker for Mn neurotoxicity. Furthermore, next-generation sequencing of serum 
exosomes showed changes in several small RNAs, such as miRNAs, piRNAs, and tRNAs that may 
potentially contribute to Mn neurotoxicity and thus could also be developed as potential 
biomarkers. Next, we further explored performance of the RT-QuIC assay on cerebrospinal fluid, 
brain homogenate, and submandibular gland homogenate samples from clinically confirmed PD 
and control subjects. We differentiated the synucleinopathy cases from control subjects with 
sensitivities and specificities exceeding those of other methods, demonstrating the potential use of 
RT-QuIC as an early diagnostic test. The reliability of this quantitative, highly sensitive and 
specific RT-QuIC assay for proteinopathies could help us in understanding the mechanisms of 







Thesis Layout and Organization 
The alternative format was chosen for this dissertation and consists of manuscripts that have either 
been published or are in preparation for submission. There is a general introduction containing one 
literature review, five research chapters in the format of their corresponding journals, and a general 
conclusions/future directions section. Each research chapter contains references at the end of each 
chapter in the format of the journal it was published, or it will be submitted to.  
In Chapter-I, we give a brief overview of proteinopathies with a focus on chronic wasting 
disease and Parkinson’s disease with available diagnostic tests. The Background and Literature 
Review provides an in-depth review of the current literature regarding the role of manganese in 
proteinopathies.  
Chapter-II is published in the journal Prion. In this research article, we reported the blinded 
study results that consists of antemortem detection of chronic wasting disease in recto-anal 
mucosa-associated lymphoid tissues from Elk (Cervus elaphus nelsoni) using Real-Time Quaking-
Induced Conversion (RT-QuIC) Assay. CWD is a prion disease that been rapidly expanding to 
several states in the USA and its zoonotic potential is still a concern.  
In Chapter-III, the robustness of RT-QuIC assay allowed me to optimize it to cell culture 
models of prion disease and tested the role of various metals especially manganese in templated 
conversion of prion protein. It reveals that manganese can exacerbate the templated conversion of 
prion protein in in-vitro and ex-vivo models of prion disease. This manuscript will be submitted to 
the journal Toxicological Sciences.  
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In chapter-IV, we used the RT-QuIC assay for detecting the misfolded α-Synuclein protein 
present in the  occupationally exposed population such as welders. Also, identified the key 
biomarkers associated with manganese neurotoxicity using the RT-QuIC assay and RNA-
sequencing analysis of exosomes. This manuscript will be submitted to journal Environmental 
Health Perspectives. 
 Chapter V is published in the journal of Neuroimmune Pharmacology, in this research 
article, we reported the ultrasensitive detection of aggregated α-Synuclein present in the glial cells, 
human cerebrospinal fluid, and brain tissue using the RT-QuIC Assay. This paper provides the 
valuable information about the use of RT-QuIC assay for the early diagnosis of Parkinson’s 
disease.  
In Chapter VI, we evaluated the diagnostic potential of pathological α-Synuclein present 
in the submandibular glands of Parkinson’s disease patients using a highly sensitive RT-QuIC 
assay. This manuscript will be submitted to journal Annals of Neurology. 
          In Chapter VII, I summarize general conclusions and pointing some important directions 
that have potential to become a valuable biomarker for early diagnosis of proteinopathies. 
This dissertation contains the experimental results obtained by the author during her Ph.D. 
study under the supervision of her major professor Dr. Anumantha G. Kanthasamy at Iowa State 






                                                                Introduction 
Proteinopathies 
Despite of several advances in the research, the molecular mechanisms underlying proteinopathies 
remain to be elucidated. Molecular hallmark of many neurodegenerative proteinopathies involves 
the misfolding and aggregation of certain proteins resulting in accumulation of abnormal protein 
aggregates that are highly resistant to degradation. Protein misfolding can result from the escape 
of  proteins from the cell’s quality control machinery under conditions such as stress, mutations or 
regular aging and leads to the formation of amyloid fibrils or aggregates (Brundin et al. 2010). 
Under normal circumstances, misfolded proteins are either degraded or refolded correctly by 
chaperone proteins but in many neurodegenerative diseases, these proteins can become 
intrinsically disordered and will aggregate into cytotoxic amyloid fibrils. In addition, amyloid 
proteins are thermodynamically stable and further initiates the conversion of native proteins into 
amyloid forms (Knowles et al. 2014). Many discoveries have provided the crucial evidence that 
misfolded protein is the main culprit of several neurodegenerative disorders including prion, 
Parkinson’s disease (PD), and Alzheimer’s disease (AD). Each disorder is characterized by the 
misfolding of specific protein: prion protein in transmissible spongiform encephalopathies (TSE), 
α-Synuclein in PD, β-amyloid and tau in AD (Table.1).  This suggests, impaired protein 
homeostasis is the common feature among all these neurodegenerative disorders and their 
intercellular transfer can contribute to the progression of each of these diseases. This can also be a 
potential target for future therapeutics. As our understanding of each disease state, in-vivo & in-
vitro modelling, and identification of  key biomarkers for the early diagnosis increases, the 




Table.1 Proteinopathies with associated misfolded proteins. 
Name of Proteinopathy Aggregating protein  
Transmissible spongiform encephalopathy  Prion  
Parkinson’s disease α-Synuclein 
Alzheimer’s disease Amyloid beta; Tau 
Tauopathies Tau 
Huntington’s disease Huntingtin with tandem glutamine repeats 
Amyotrophic lateral sclerosis Superoxide dismutase 1 
 
1. Prionopathies 
Prionopathies are due to the aggregation of a small cellular protein with unknown function known 
as prion protein (PrP). The term “prion” can be defined as a small proteinaceous infectious particle 
that is resistant to conventional inactivation procedures (Prusiner 1982). The disease is 
characterized by the conversion of normal cellular prion protein (PrPC) into misfolded prion 
protein (PrPres) and this PrPres is thought to serve as a template to trigger the further catalytic 
conversion of PrPC (Prusiner 1982). PrPC is a globular protein and anchors to the outer surface of 
the cell membrane with a glycosyl-phosphatidyl-inositol (GPI)(Stahl et al. 1992). It consists of the 
alpha-helix-rich region towards the C-terminal and octapeptide repeat regions at the N-terminus. 
During the conversion of PrPC into PrPres the alpha-helix-rich region will be converted into beta-
sheets that gain protease resistance (Miura et al. 1996). PrPres remains to be the main pathological 
event in all prion diseases and associated with neurobehavioral changes and spongiform 
vacuolation of central nervous system (Aguzzi and Polymenidou 2004; Collinge 2005; Prusiner 
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1998; Weissmann 2004). The exact physiological function of PrPC is not known but it is known to 
be involved in myelin maintenance, cell signaling, apoptosis, metal homeostasis, and oxidative 
stress (Anantharam et al. 2008; Choi et al. 2010; Choi et al. 2007; Harischandra et al. 2014). Prion 
diseases are characterized by the accumulation of aggregated prion proteins. Prion diseases can be 
infectious, sporadic or genetic. Sporadic and genetic forms develop spontaneously. Prion diseases 
mainly consists of Creutzfeldt-Jakob disease (CJD) and kuru in humans (Siedler and Malamud 
1963), chronic wasting disease (CWD) in cervids (Williams and Young 1982), scrapie in sheep 
(Bolton et al. 1982), and bovine spongiform encephalopathy in cattle (Hope et al. 1989). 
Chronic wasting disease 
Chronic wasting disease (CWD) is a type of transmissible spongiform encephalopathy (TSE) that 
affects a wide range of captive and wild cervids such as elk, white-tailed deer, mule deer, moose, 
muntjac, reindeer (Baeten et al. 2007; Benestad et al. 2016; Nalls et al. 2013; Williams 2005; 
Williams and Young 1980) and experimentally be transmitted to swine (Moore et al. 2017). CWD 
was first identified in Colorado and has since expanded to several states and territories of North 
America including Iowa, Wisconsin and Illinois (Williams and Young 1980; 1982). CWD has also 
been reported in South Korea, Canada and very recently in Norway (Benestad et al. 2016). CWD 
achieves efficient horizontal transmission to neighboring animals because PrPres becomes widely 
distributed among the lymph nodes, nervous tissue,(Perrott et al. 2012; Williams 2005; Williams 
and Young 1992) blood, (Orru et al. 2011) and it is also excreted in other body fluids where it 
persists in the environment.(Haley et al. 2009a; Henderson et al. 2013; Nichols et al. 2009) The 
presence of abnormal PrPD serves as an important marker to diagnose CWD. In white-tailed deer, 
PrPD accumulation in brain tissues is preceded by its accumulation in several lymphoid tissues like 
tonsils, lymph nodes, and gut-associated lymphoid tissue (Keane et al. 2009; Keane et al. 2008). 
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Thus, given the potential for earlier detection, this peripheral tissue distribution was exploited in 
the utilization of rectal biopsies for antemortem screening of scrapie, thus helping surveillance 
programs in Canada and the US since 2006 and 2008, respectively. Due to the rapid and 
widespread nature of CWD in captive and free-ranging animals, the serious concern that needs to 
be addressed is how to detect the disease early enough in live animals from both captive and wild 
populations for intervention measures to halt the spread of the disease (Jennelle et al. 2014; Nichols 
et al. 2009). 
Diagnosis of CWD 
Current gold standard testing for prion disease is based on characteristic post-mortem lesions such 
as 1.histopathologic changes of gray matter associated with the central nervous system and/or 
MRP lymph nodes, 2. intracytoplasmic vacuolation, 3. neuronal degeneration and 4. Presence of 
PrPres amyloid aggregates that are stained using antibodies or staining dyes such as ThT and Congo 
red (Sigurdson and Aguzzi 2007).  
A. Immunoassays 
After identification of PrPres as the causative agent for TSE’s, several diagnostic assays were 
developed based on antigen-antibody assays. These tests include western blotting, 
immunohistochemistry and enzyme immunoassay (EIA) considered as “gold standard” for prion 
diagnosis(Guiroy et al. 1993; Guiroy et al. 1991; Hibler et al. 2003). Presence of proteinase K 
resistant core in PrPres after treating with harsh conditions like acid and enzymatic digestion is the 
main principle present in all the above diagnostic tests. In western blotting, analysis of proteinase-
K digested samples by SDS-PAGE reveals the presence of characteristic di-, mon-, and 
unphosphorylated PrPres of 21-27 kD in size(Kurt et al. 2007). Due to the presence of 
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immunoreactivity associated with PrPres protein(Guiroy et al. 1993), several antibody-based 
immunohistochemical techniques were evolved using tissues like the obex region of the brain stem 
and medial retropharyngeal lymph nodes (RLN). In deer, RLN becomes positive earlier than obex 
whereas in elk obex may be positive without in RLN(Keane et al. 2008; Spraker et al. 2004). Other 
lymphoid tissues like tonsils and recto anal mucosa associated lymphoid tissues (RAMALT) also 
serves as an important diagnostic sample for CWD (Manne et al. 2017). To further characterize 
the CWD pathogenesis and routes of transmission, it is important to evaluate the biological fluids 
like blood, urine, saliva, and feces. But due to the difficulty associated with detection of PrPres with 
the conventional immunodetection methods, adopted the bioassays for knowing the infectivity 
associated with these samples. In bioassays, natural and experimental animals will be exposed to 
the inoculum and uncover the disease transmission and infectivity associated with the samples like 
blood (Mathiason et al. 2010), urine, feces(Haley et al. 2009a; Haley et al. 2009b) and saliva 
(Mathiason et al. 2006). With the help of immunoassay and bioassay’s, we gained knowledge 
related to CWD pathogenesis and likely routes of transmission. However, approaches that imitate 
the protein misfolding and amplification of low levels of misfolded proteins to easily detectable 
levels would need to be developed to further advance the diagnosis. 
B. Amplification assays                                                                                                                                                                             
The basic principle behind these techniques include the PrPres present in the sample will convert 
the normal PrPC into a misfolded one and amplifies the low levels of misfolded prions to a 
detectable level. 
i. Protein misfolding cyclic amplification (PMCA) 
This is the first amplification technique adapted for diagnosing CWD. This assay requires the 
substrate, PrPC derived from the brain homogenates of susceptible hosts like transgenic mice 
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expressing the cervidized prion protein and seed consists of a testing sample. Substrate and seed 
mixture will be incubated at 37oC and sonication step is used intermittently to disrupt the growing 
fibrils for providing seeds to catalytically convert the PrPC into misfolded prion protein(Kurt et al. 
2007). After each round of incubation, the substrate-seed mixture will be treated with proteinase-
K to digest the unwanted proteins and the rest will be separated by SDS-PAGE to visualize the 
banding pattern. To advance the detection limits of PMCA in samples having very low levels of 
misfolded proteins, proteinase-K resistant fractions will be sub passaged with the brain 
homogenate up to 10 cycles instead of immediate gel separation. This improved version is called 
as serial PMCA (sPMCA)(Castilla et al. 2006). Several improvements have been made to PMCA 
and sPMCA to improve the sensitivity and one group used surround optical fiber immunoassay 
(SOFIA) to detect the PrPres instead of traditional proteinase-k digestion experiments(Rubenstein 
et al. 2010). With the help of PMCA assessed the low-levels of infectivity associated with body 
fluids(Haley et al. 2009a; Mathiason et al. 2006), soil(Saunders et al. 2011) and water(Nichols et 
al. 2009). However, the use of animal hosts for the substrate, time-constraints and difficult read-
outs associated with the assay are important considerations needed to be addressed with further 
advancements. 
ii. Quaking induced conversion assay 
With criteria of meeting above recommendations, another technique named the quaking induced 
conversion (QuIC) assay has been developed by Caughey and colleagues (Atarashi et al. 2007). In 
this technique, the substrate can be easily and consistently obtained by expressing in cellular 
systems like E. Coli and purified by using recombinant protein purification methods. A most 
common form of substrate used for testing human and animal tissues is truncated Syrian hamster 
prion protein and other modifications can be made very easily to the substrate (Atarashi et al. 
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2008). This technique is further advanced by adding Thioflavin T (ThT) dye which will bind to 
the amyloid aggregates and change in fluorescence readings will be detected in real-time using a 
plate reader. This enhanced technique is known as real-time quaking induced conversion (RT-
QuIC) assay. The experiment is carried out at 42oC in a 96-well plate and readings will be taken 
for every 30 min using an excitation and emission reading of 450 and 480 nm, respectively. To 
further initiate the catalytic seeding, amyloid fibrils will be degraded by shake and rest protocols 
of the 96-well plate. With all these advancements, a highly sensitive and high through-put 
diagnostic approach for CWD diagnosis is implemented. Using the RT-QuIC assay, amyloid 
seeding activity was detected with improved sensitivity and specificities in tissues like retina (West 
Greenlee et al. 2016) and antemortem samples like RAMALT (Manne et al. 2017).  
2. Synucleinopathies 
Synucleinopathies are a group of proteinopathies that shares a common pathological feature 
characterized by the presence of aggregates of α-Synuclein (αSyn) in the neurons and glia (Galvin 
et al. 2001). αSyn is a small, 14.5-kDa acidic protein of synuclein family, comprising 140 amino 
acids, encoded by a single SNCA gene present on the Chromosome 4. αSyn is expressed in the 
presynaptic terminals of neurons with a function role of maintaining synaptic plasticity, dopamine 
regulation and membrane trafficking. The other members of synuclein family include β-
Synuclein, γ-Synuclein and synoretin (Tu et al. 1998).  There has been no evidence to suggest the 
involvement of  β-Synuclein and γ-Synucleins in neurological disease (Galvin et al. 1999).  
Synucleinopathies mainly consist of Parkinson’s disease (PD), dementia with Lewy bodies (DLB) 
and multiple system atrophy (MSA). In PD and DLB αSyn aggregates accumulate in the neurons 
as Lewy bodies and Lewy neurites (Spillantini et al. 1998) where as in MSA, αSyn aggregates 
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accumulate in the oligodendrocytes as glial cytoplasmic inclusions (GCI) (Tu et al. 1998). This 
suggests that  αSyn could play a major role in the pathogenesis of synucleinopathies.  
Parkinson’s disease 
Parkinson’s disease (PD) is a second most common neurodegenerative disorder, estimated to 
affect 10 million people worldwide, and increasing by 60,000 new cases annually affecting elderly 
population over 60 years of age (Dauer and Przedborski 2003; Mizuno et al. 2001). Early onset 
PD has been linked with mutations in various 
genes including α-synuclein, Parkin, leucine 
rich repeat kinase 2 (LRRK2), PINK1, and 
DJ-1 (Bonifati et al. 2008; Gwinn-Hardy 
2002; Tang et al. 2006; Weng et al. 2007). 
The histological hallmark  features of the 
disease include, loss of dopaminergic neurons 
in the substantia nigra (SN), loss of dopamine 
in the axon terminals in the striatum, and 
accumulation of aggregates  
of alpha-synuclein in the form of Lewy bodies and Lewy neurites (Spillantini et al. 1998). The 
association between αSyn and PD pathogenesis is based on the identification of aggregates of 
αSyn as a major constituent in the Lewy bodies and Lewy neurites of sporadic and familial cases 
of PD (Roth et al. 2013). Also, compelling evidence demonstrates that mutations in the gene 
encoding α-Syn are directly linked to the onset of PD (Liu et al. 2012).  Additionally, rare familial 
forms of PD also occur due to overexpression of αSyn due to duplication or triplication of the 
SNCA gene. 
Figure 1. Contributing factors in PD 
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Diagnosis of Parkinson’s disease 
There is no definitive test available for the diagnosis of PD. Hence, the disease must be diagnosed 
based on the through neurological examination to identify cardinal clinical signs such as  
bradykinesia, resting tremor, rigidity, and postural instability. Other clinical and nonmotor 
symptoms include sleep disorders, sensory abnormalities such as anosmia, mood disorders such 
as depression and anxiety. The presence of these clinical signs will help in differentiating PD from 
other PD related parkinsonian disorders (Jankovic 2008). A myriad of genetic, epigenetic and 
environmental factors (Fig. 1) interact to cause idiopathic disease resulting in nigrostriatal 
neurodegeneration (Pissadaki and Bolam 2013), mitochondrial dysfunction, oxidative stress, and 
neuroinflammation ultimately leading to pathophysiological processes in PD  (Subramaniam and 
Chesselet 2013; Varçin et al. 2012). Tests such as identifying genetic mutations, neuroimaging 
abnormalities, response to Levodopa treatment,  and other αSyn related biomarkers will help in 
identifying the people that are at risk.  
Key biomarkers 
To date, there are several biomarkers identified through various biased and unbiased approaches 
to facilitate the PD diagnosis. Some of these include, 
A. α-Synuclein 
αSyn is the main protein present in the Lewy bodies of PD cases. Moreover, mutations of the gene 
associated with the αSyn causes development of PD (Polymeropoulos et al. 1997). Extensive 
efforts have been made to identify the αSyn present in the cerebrospinal fluid (CSF) of PD cases 
and its use as a diagnostic biomarker (Mollenhauer et al. 2013). Mollenhauer et al., measured the 
levels of αSyn present in the CSF of PD and healthy cases using an enzyme linked immuono 
sorbent assay (ELISA) and found the lowered levels of total αSyn in PD patients compared to 
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healthy controls. Other forms of αSyn such as oligomeric or phosphorylated forms of αSyn were 
increased in the CSF of PD patients compared to controls (Hansson et al. 2014). Overall, a clear 
trend of decreased total αSyn levels and increased oligomeric or phosphorylated αSyn levels in in 
the CSF samples of PD compared to controls were reported (Mollenhauer et al. 2011; Parnetti et 
al. 2011; Tokuda et al. 2006). In a similar manner total, oligomeric and phosphorylated forms of 
αSyn (El-Agnaf et al. 2006; Foulds et al. 2011; Tinsley et al. 2010), have also been reported in 
the plasma, demonstrating the potential biomarker role for αSyn.  Immunohistochemical detection 
of phosphorylated αSyn in the submandibular glands is another promising approach established 
for the diagnosis of PD (Beach et al. 2013). 
In the last few years, several efforts have been carried out to develop a diagnostic test for 
ultrasensitive quantification of αSyn aggregates present in the brain tissues and biological fluids. 
Among these, protein amplification assays such as protein-misfolding cyclic amplification 
(PMCA) assay and real-time quaking induced conversion (RT-QuIC) assays have been adopted 
from the human prion diagnosis to detect misfolded αSyn. These two assays work on the principle 
of protein misfolding mechanism. αSyn-PMCA was used to detect the αSyn aggregates present 
in the CSF samples (Shahnawaz et al. 2017) and brain homogenates (Becker et al. 2018) from 
synucleinopathy cases. Similarly, sensitivity of αSyn RT-QuIC assay was investigated by 
detecting the αSyn aggregates present in the CSF (Groveman et al. 2018; Manne et al. 2019) and 
brain homogenate (Fairfoul et al. 2016; Manne et al. 2019)samples using synucleinopathy and 
non-synucleinopathy cases. 
B. DJ-1 
Mutations of the gene encoding the protein, DJ-1 was identified in familial cases of PD (Bonifati 
et al. 2003). The function of the DJ-1 is unknown and it is a regulatory subunit of an RNA-binding 
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protein (Hod et al. 1999). Based on the results of sensitive Luminex assays by Hong Z etal., the 
levels of DJ-1 and αSyn were dependent on the age and decreased in the PD patients compared to 
controls (Hong et al. 2010). Quantification of serum DJ-1levels using an ELISA did not yield a 
significant difference between PD and controls (Maita et al. 2008). However, quantifying plasma 
DJ-1 levels using modified multiplex immunoassay yielded much higher sensitivities than 
traditional western blotting and ELISA. The source of plasma DJ-1 and αSyn were found to be 
from red blood cells. There was decreasing trend in levels of DJ-1 in PD patients compared to 
controls but not statistically significant. Also, total DJ-1 levels in plasma alone is not a useful 
biomarker for PD  (Shi et al. 2010). Whereas, levels of other isoforms of DJ-1, 4-hydroxy-2-
nonenal modified DJ-1 identified using two-dimensional gel electrophoresis and immunoblotting 
techniques were significantly different between PD and controls (Lin et al. 2012).  
C. Apolipoprotein A1 (ApoA1) 
Lower levels of ApoA1 was observed in the plasma of symptomatic PD patients and in individuals 
with reduced dopamine transporter levels (Qiang et al. 2013) measured by multiplex 
immunoassay. Use of ApoA1 modifying medications such as statins have shown to cause the 
modest reduction in PD risk in a prospective study (Gao et al. 2012). The results from these studies 
identified ApoA1 as a potential candidate biomarker.  
3. Tauopathies 
Tauopathies are a group of neurodegenerative disorders characterized by the presence of 
aggregates of tau protein in neurons and glial cells. Tau is a tubular protein essential for stability 
of neuronal cells. Posttranslational modification of tau protein leads to its hyperphosphorylation 
and initiates the formation of tau aggregates in the form of neurofibrillary tangles and helical 
filaments (Weingarten et al. 1975). Tau is encoded by MAPT gene and 6 isoforms of tau has been 
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expressed by alternative splicing (Goedert et al. 1989). The 6 isoforms differ from each other by 
the presence of either three (3R) or four (4R) tandem repeat sequences of 31 or 32 amino acids. In 
patients, filaments were composed of either 3R or 4R or both indicating the heterogeneity of 
tauopathies (Sergeant et al. 2005). Tauopathies majorly consists of frontotemporal dementia 
(FTD), corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), Pick disease (PiD) 
and Alzheimer’s disease (AD). In AD, along with tau neuropathology, amyloid beta (Aβ) plaques 
also observed (Irwin 2016).  
                                         Background and Literature Review 
Manganese  
Manganese (Mn) is a trace element essential for normal cellular development, homeostasis and 
growth (Erikson et al. 2005). It functions as a cofactor for several enzymes involved in metabolism 
and synthesis (Butterworth 1986). Deficiency of Mn can lead to impaired fertility, birth defects, 
bone malformation (Aschner et al. 2002). Mn is found in the diets such as whole grains, nuts, tea, 
legumes, pineapple and beans. Excessive Mn exposure can lead to accumulation in the brain 
especially basal ganglia (Aschner et al. 2007). Excessive exposure to Mn occurs through 
occupations such as welding and mining, inhalation of combustible products, and higher 
concentrations in ground water. Enzymes such as glutamine synthetase, superoxide dismutase 2 
(SOD2), and pyruvate decarboxylase functions only in the presence of Mn (Takeda 2003). 
Manganese and prions 
Cellular prion protein, PrPC is a metalloprotein with octapeptide repeat sequences at the N-terminal 
region (Fig. 2). It has very high affinity for divalent cations such as copper (Cu), Mn and Zinc 
(Zn). Binding of Mn to recombinant PrPC changed its conformation to PrPres. However, this affect 
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was abolished after deletion of octapeptide repeat sequences indicating the importance of these 
repeat sequences in mediating Mn and prion interactions (Brown et al. 2000). Although Mn has 
binding affinity to the octameric repeat region, results from some studies showed no affinity for 
Mn to octapeptide repeat region (Garnett and Viles 2003; Treiber et al. 2006). Contrary to these 
findings, NMR and CD spectroscopy analysis confirmed the binding of Mn to octapeptide repeats 
but in lesser magnitude compared to Cu (Jackson et al. 2001) and also identified His 95 as the 
preferential binding site of PrP for Mn (Brown 2009). Using isothermal titration calorimetry, two 
Mn binding sites for were identified for the PrP. One is located at histidine residue 95 with 
dissociation constant of 63 µM and the second low-affinity site is present in the octameric repeat 
region with dissociation constants of 200 μM (Brazier et al. 2008). Studies using PMCA technique 
showed that Mn acts as a cofactor for the conversion of PrPC to PrPres (Kim et al. 2005). Addition 
of Mn-containing media to the PrP-expressing yeast cell system induced the formation of PrPres, 
suggesting that environmental Mn could be a risk factor for prion disease (Treiber et al. 2006).  
 
Despite these extensive in vitro studies on prion-Mn interaction and its subsequent effects on prion 
aggregation, the in vivo consequences of Mn binding to prion in terms of neuronal loss have not 
yet been well studied. Recently, studies showed that Mn can cause recombinant PrP refolding in 
cell culture models (Uppington and Brown 2008) and treatment with selective chelator for Mn, 
cyclohexanediaminetetraacetic acid (Na2CaCDTA), extended the life in an animal model of prion 
Figure 2: Structure of a cellular prion protein 
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disease (Brazier et al. 2010). Furthermore, feeding with Mn-rich diet in Scrapie prion-inoculated 
mice increased neuronal damage (Hortells et al. 2010). In addition,  elevated levels of Mn were 
noticed in the brain and blood of humans and animals infected with various prionopathies (Hesketh 
et al. 2008; Hesketh et al. 2007; Kim et al. 2005; White et al. 2010; Wong et al. 2001). Indeed, we 
lack a clear evidence for elevated Mn levels in these prion disease cases suggesting that Mn toxicity 
might be responsible for TSE-related neuronal loss. A greater understanding of environmental 
determinants would greatly help in assessing the risk factors of TSE.  
Manganese and PD 
Mn exposure has been implicated as a risk factor for various neurological disorders, including PD 
(Haynes et al. 2015; Lucchini et al. 2014; Sanders et al. 2015; Sikk and Taba 2015). Occupational 
exposure to Mn is the principal cause of Mn intoxication in humans working in ceramics, welding, 
steel making and mining industries (Mielke et al. 2002; Yabuuchi and Komaba 2014). Excessive 
exposure to manganese or failure to excrete it can cause accumulation of manganese in the basal 
ganglia leading to manganism, a movement disorder similar to PD (Bouabid et al. 2015; Peres et 
al. 2016). Symptoms of manganism include motor deficits such as rigidity and bradykinesia, 
patients present a characteristic “cock-walk” gait (Bowler et al. 2006; Bowler et al. 1999; Kwakye 
et al. 2015). Unlike PD, manganism affects the neurons located in the globus pallidus (Criswell et 
Figure 3: Structure of a α-Synuclein protein 
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al. 2015; Perl and Olanow 2007) and patients with manganism respond poorly to levodopa therapy, 
hence chelation therapy is an alternative (Discalzi et al. 2000; Ky et al. 1992) 
αSyn is a metalloprotein with three regions include, amphipathic N-terminal region (residues 1-
60), NAC region (residues 61-95) and acidic C-terminal region (residues 95-140) (Rokad et al. 
2017) (Fig. 3). Out of these, amphipathic region contains consensus sequence of KTKEGV repeats 
essential for α-helix formation (Lazaro et al. 2014). Common mutations associated with familial 
PD including A30P, A53T, and E46K were due to point mutations in the N-terminal region (Zarbiv 
et al. 2014).  Central NAC region is essential for protein aggregation (Zarbiv et al. 2014) and 
finally the C-terminal region is rich in proline and responsible for intrinsically disordered nature.  
Among the three metal binding sites, binding sites located at the N-terminal domain, specifically 
the 1MDVFMKGLS9 and 48VAHGV52 regions, demonstrated high-affinity binding for Cu2+ (Kd ∼ 
0.1 μM) (Rasia et al. 2005) whereas metal binding sites near 49–52 and 110–140 are known to 
interact with divalent metals including manganese (Binolfi et al. 2008; Binolfi et al. 2006; Uversky 
et al. 2001). Furthermore, binding of Mn3+ to αSyn protein induced immediate di-tyrosine 
formation, suggesting the role of Mn for the metal-induced oxidation of αSyn protein. All these 
results showed the basis of metal interaction with αSyn suggesting that alterations in metal 
homeostasis could become a major event in  proteinopathies and understanding the 
pathophysiological process can help to prevent or delay the disease onset and progression (Binolfi 
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Abstract 
Prion diseases are transmissible spongiform encephalopathies (TSEs) characterized by fatal, 
progressive neurologic disease with prolonged incubation periods and an accumulation of 
infectious misfolded prion proteins. Antemortem diagnosis is often difficult due to a long 
asymptomatic incubation period, differences in the pathogenesis of different prions, and the 
presence of very low levels of infectious prion in easily accessible samples. Chronic wasting 
disease (CWD) is a TSE affecting both wild and captive populations of cervids, including mule 
deer, white-tailed deer, elk, moose, muntjac, and most recently, wild reindeer.  This study 
represents a well-controlled evaluation of a newly developed real-time quaking-induced 
conversion (RT-QuIC) assay as a potential CWD diagnostic screening test using rectal biopsy 
sections from a depopulated elk herd. We evaluated 69 blinded samples of recto-anal mucosa 
associated lymphoid tissue (RAMALT) obtained from USDA Veterinary Services. The results 
were later un-blinded and statistically compared to immunohistochemical (IHC) results from the 
USDA National Veterinary Services Laboratories (NVSL) for RAMALT, obex, and medial 
retropharyngeal lymph node (MRPLN). Comparison of RAMALT, RT-QuIC assay results with 
the IHC results of RAMALT revealed 92% relative sensitivity (95% confidence limits: 61.52-
99.8%) and 95% relative specificity (95% confidence limits: 85.13-99.%). Collectively, our results 
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show a potential utility of the RT-QuIC assay to advance the development of a rapid, sensitive, 
and specific prion diagnostic assay for CWD prions. 
Keywords  
Ante-mortem test, chronic wasting disease (CWD), elk, immunohistochemistry (IHC), medial 
retropharyngeal lymph node (MRPLN), obex, prion, real-time quaking-induced conversion (RT-
QuIC) assay, recto-anal mucosa associated lymphoid tissue (RAMALT).  
Introduction 
Chronic wasting disease (CWD) is a type of transmissible spongiform encephalopathy (TSE) that 
affects a wide range of captive and wild cervids such as elk, white-tailed deer, mule deer, moose, 
muntjac, reindeer(Baeten et al. 2007; Benestad et al. 2016; Nalls et al. 2013; Williams 2005; 
Williams and Young 1980) and experimentally be transmitted to swine.(Moore et al. 2017a) CWD 
was first identified in Colorado and has since expanded to several states and territories of North 
America including Iowa, Wisconsin and Illinois.(Williams and Young 1980; 1982) CWD has also 
been reported in South Korea, Canada and very recently in Norway.(Benestad et al. 2016) 
Conversion of normal cellular prion protein (PrPC) into its abnormally folded isoform, disease-
associated prion protein (PrPD), results in protease resistance and the consequent accumulation of 
PrPD, which serves as the diagnostic marker to identify prion infectivity.(Prusiner 1998a; Zhou 
and Xiao 2013) PrPC is involved in various biological functions such as cell signaling, metal 
homeostasis, apoptosis and oxidative stress.(Anantharam et al. 2008; Choi et al. 2010; Choi et al. 
2007; Harischandra et al. 2014) CWD achieves efficient horizontal transmission to neighboring 
animals because PrPD becomes widely distributed among the lymph nodes, nervous tissue,(Perrott 
et al. 2012; Williams 2005; Williams and Young 1992) blood, (Orru et al. 2011) and it is also 
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excreted in other body fluids where it persists in the environment.(Haley et al. 2009; Henderson et 
al. 2013; Nichols et al. 2009) The presence of abnormal PrPD serves as an important marker to 
diagnose CWD. In white-tailed deer, PrPD accumulation in brain tissues is preceded by its 
accumulation in several lymphoid tissues like tonsils, lymph nodes, and gut-associated lymphoid 
tissue.(Keane et al. 2009; Keane et al. 2008) (Balachandran et al. 2010) Thus, given the potential 
for earlier detection, this peripheral tissue distribution was exploited in the utilization of rectal 
biopsies for antemortem screening of scrapie, thus helping surveillance programs in Canada and 
the US since 2006 and 2008, respectively. 4, 5 Due to the rapid and widespread nature of CWD in 
captive and free-ranging animals, the serious concern that needs to be addressed is how to detect 
the disease early enough in live animals from both captive and wild populations for intervention 
measures to halt the spread of the disease.(Jennelle et al. 2014; Nichols et al. 2009) To date, several 
diagnostic methods have been approved as official regulatory test methods in the US to detect 
PrPD, such as immunohistochemistry (IHC), Western blot, and ELISA.  However, the utility of 
these assays is limited to postmortem tissues (such as obex and medial retropharyngeal lymph 
nodes) in the case of cervids with CWD.  
New protein-misfolding amplification platforms such as real-time quaking-induced conversion 
(RT-QuIC) and serial protein-misfolding cyclic amplification (PMCA) assays have recently been 
evaluated for their utility in detecting PrPD, as well as for their sensitivity and specificity. However, 
the diagnostic utility of these techniques has not been rigorously tested for cervid biopsies. The 
RT-QuIC and PMCA assays show great promise for developing new tests that will enable us to 
detect prion disease early in live animals.(Atarashi et al. 2007; Saborio et al. 2001) Furthermore, 
the RT-QuIC assay is well documented for its flexibility and versatility utilizing a high-throughput 
format. To detect PrPD in CWD cases, most of the current diagnostic methods use brainstem, 
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medial retropharyngeal lymph node (MRPLN), and palatine tonsils from postmortem animals. In 
white-tailed deer and elk, utilizing recto-anal mucosa associated lymphoid tissue (RAMALT) and 
other lymphoid tissue biopsies provides promising sample tools for antemortem diagnosis of 
CWD.  Also, collecting RAMALT from live animals is a relatively simple and reliable procedure 
that has already been adopted for use in experimental animals and sheep populations and could be 
translated to field conditions for both captive and wild cervid management.(Keane et al. 2009; 
Spraker et al. 2009; Wild et al. 2002; Wolfe et al. 2007), (Espenes et al. 2006; Gonzalez et al. 2005) 
Despite these advancements in diagnosing prion diseases, several challenges still need to be 
addressed for sensitive and specific detection of CWD in early stages of infection. 
In the present study, researchers from Iowa State University, USDA Wildlife Services, and USDA 
Veterinary Services employed a blinded study design to evaluate the ability of the RT-QuIC assay 
to detect CWD from post-mortem RAMALT samples in an elk herd of 69 animals depopulated 
due to CWD infection. The RAMALT RT-QuIC assay results correlated well with the IHC 
detection of PrPD from the RAMALT and with the severity of prion infection. Our study identifies 
RAMALT samples as a suitable candidate for the RT-QuIC assay and compares RT-QuIC with 
currently approved testing methods. Our results demonstrate that RAMALT could be adopted for 
the antemortem diagnosis of CWD. With the validation of RT-QuIC assay for RAMALT samples, 
CWD could be diagnosed from live elk, increasing the number of strategies available to prevent 
the spread of the disease. 
Results 
Determination of quality of substrate used for RT-QuIC assay   
The purity of substrate is a key determinant of protein misfolding kinetics in the RT-QuIC assay. 
Therefore, we first tested the purity of our in-house generated, Syrian Hamster recombinant prion 
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protein (SHrPrP) (residues 90-231). The high-purity recombinant prion protein was generated 
using the bacterial expression system and isolated by affinity chromatography under denaturing 
conditions, and on-column refolding followed by elution of protein (as described in methods, Fig. 
1A, top panel). Biochemical characterization of the SHrPrP using total protein stain (Ponceau) 
revealed that the protein was maximally pure (Fig. 1A, middle panel). We also performed Western 
blot analysis of the purified protein using a mouse monoclonal 6D11 antibody, which revealed a 
single band specific for PrP immunoreactivity at ~16 kD molecular weight (Fig. 1A, bottom panel). 
Additionally, we used SHrPrP (residues 90-231) received from Dr. Caughey and colleagues from 
the NIH Rocky Mountain Laboratory(Wilham et al. 2010a) as a positive control. This was loaded 
in lane 8 of the Western blot (Fig. 1A), corresponding to the same molecular weight as our lab-
purified protein in lane 6 (center of the peak fraction during elution of protein), which was used in 
the RT-QuIC assay. Total protein stain and Western blot analysis of SHrPrP from our lab and the 
positive control from Caughey’s lab are shown in Fig. 1B. Next, we performed biophysical 
characterization of the substrate using NMR spectroscopy. The spectra revealed the purity and 
homogeneity of the substrate and conformation of the alpha helical-rich protein (Fig. 1C). 
Furthermore, CD spectroscopy of the purified protein confirmed the high α-helical content of its 
secondary structure (Fig. 1D). For NMR and CD spectroscopy, we also plotted our lab-purified 
protein against positive controls from the Caughey lab. Lastly, mass spectroscopy indicated >99% 
purity of the rPrP (data not shown). 
Along with other confirmatory tests, we also compared purified protein in the RT-QuIC assay, 
from which it is evident that both the reference protein and purified protein have similar amyloid 
formation rates (AFR) (Fig. 1E). AFR was derived by taking the inverse of the time to cross the 
threshold fluorescence, which was defined as the control mean fluorescence plus 5 standard 
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deviations.(Haley et al. 2014) Every purified batch of the rPrP90-231 was validated using total 
protein stain, Western blotting and test plates with known standards before using in the RT-QuIC 
assay.  
Optimal seed concentration of recto-anal mucosa associated lymphoid tissue (RAMALT) 
samples for RT-QuIC analysis 
As in many assays, it is imperative to quantify the amount of seed needed for the assay. Too much 
or too little seed may reduce the sensitivity of the RT-QuIC assay. Therefore, to determine the 
optimal seed concentration of an RAMALT sample that works best in the RT-QuIC assay, we did 
a serial log dilution of a known positive control RAMALT sample. The sample was homogenized 
with phosphate buffered saline (PBS) to 10% and later diluted (in 0.05% SDS/PBS) to generate 
concentrations (%) of 2, 2 x 10-1, 2 x 10-2, 2 x10-3, 2 x10-4 and so on until 2 x 10-7. From each 
serially diluted homogenate, 5 µl was added to 95 µl of the RT-QuIC reaction mixture (described 
in Methods), thus further diluting the seed in the well. Seed concentrations of 2X10-2 and 2X10-3 
amplified optimally compared to all other dilutions, which amplified at later time points (Fig. 2A).  
When different seed concentrations from the serial dilution were plotted against the AFR, a linear 
relationship was observed for those seeded with a positive control.  High AFR values indicate the 
sample is crossing the threshold at an early time point and has a low lag period, making it more 
suitable for testing. Threshold-crossing time for any sample depends on its seed concentration. No 
amyloid was formed when negative seeds were used (Fig. 2B). All RAMALT samples from 69 
elk were tested using 2X10-2 dilution in the RT-QuIC assay (Fig. 2C & 2D). The RT-QuIC 
fluorescence amplification readout showed a clear increase in fluorescence intensity in CWD-




CWD status of the herd 
Immunohistochemical (IHC) analysis of obex, MRPLN, and RAMALT (Fig 3A and 3B) were 
independently performed in all 69 elk samples at the National Veterinary Services Laboratories, 
but the RT-QuIC analysis was done at Iowa State University and only for RAMALT samples. Out 
of 69 elk, 51 were MM, and 17 were ML genotypes at codon 132 in the Prnp gene; genotyping 
data was not available for one animal, only 68 animals were used for data analysis (Table 1). 
Among the 51 MM animals, IHC analyses identified 14 animals that were CWD-positive in both 
the obex and MRPLN, one in obex sample only, and six in MRPLN only. For RAMALT samples, 
both IHC and the RT-QuIC assay identified 10 animals that were positive by IHC of obex and 
MRPLN. Of the 17 ML animals, IHC analyses identified 2 animals that were CWD-positive in 
IHC of both the obex and MRPLN, two obex only. However, IHC and RT-QuIC analyses of 
RAMALT samples only identified 2 animals as CWD-positive (Table 1). This discrepancy in PrPD 
detections when comparing RAMALT results to those of obex and MRPLN may be due to lack of 
PrPD in tested samples. Samples positive by IHC analysis of obex were scored as 0, 1, 2, 3 & 4 
based on a previously reported methodology(Thomsen et al. 2012) (Table 1). Collectively, 19/68 
(28%) elk samples were CWD-positive by IHC of obex, and 22/68 (32%) were positive by IHC of 
MRPLN.   Notably, out of these positive animals, IHC of RAMALT identified 12 positives, and 
RT-QuIC analysis of RAMALT identified 14 positives. 
RAMALT RT-QuIC and IHC test results 
Based on genotyping and other diagnostic test results, CWD is more prevalent in animals 
homozygous for MM at the Prnp codon 132 since more positives were observed in MM animals 
compared to those with the ML genotype (Fig. 4A). This is consistent with the previous 
reports(Haley et al. 2016),(Hamir et al. 2006). To evaluate the RAMALT RT-QuIC results, we used the 
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Receiver Operating Characteristics (ROC) curve, which plots sensitivity versus 1-specificty of a 
diagnostic test. The specificity of RT-QuIC versus a diagnostic test (e.g., IHC) is calculated as 
TN/(TN+FP), where TN (true negative) is the number of samples identified as negative (not 
infected) by both tests and FP (false positive) is the number of samples identified as positive 
(infected) by RT-QuIC but negative by the other test (e.g., IHC). The area under the curve (AUC) 
represents the accuracy of the test and offers a way to quantitatively compare two or more 
diagnostic tests. Here, we compared the RAMALT RT-QuIC results with IHCs of RAMALT, 
obex, and MRPLN samples. In general, an AUC >90% indicates high accuracy. IHC of RAMALT 
and RAMALT RT-QuIC assay (Fig. 4B) share 93.1% AUC. Thus, RAMALT RT-QuIC assay 
results were closely comparable to RAMALT IHC results. Overall, the correlation between IHC 
of RAMALT and those of RT-QuIC analyses was nearly 81% (Table 2). By comparing RAMALT 
samples, the relative sensitivity and relative specificity of the RT-QuIC assay and IHC were 92% 
and 95%, respectively. The sensitivity of the RT-QuIC assay for RAMALT samples with other 
tests like IHC’s of obex and MRPLN is 50% along with 95% specificity. 
Discussion  
The lack of an antemortem diagnostic test for CWD is a concerning problem. CWD’s widespread 
nature and very long incubation period warrants the pressing need for a robust antemortem test for 
early diagnosis, which would reduce much of the uncertainty plaguing modern herd management. 
Recently, the RT-QuIC assay has been experimentally used for diagnosing Creutzfeldt–Jakob 
disease (CJD)(Orru et al. 2015a), scrapie(Dassanayake et al. 2016), and CWD.(Cheng et al. 2016) 
Very recently, we have reported that the RT-QuIC assay can be readily adopted for a rapid 
detection of prion infection using an ex vivo brain culture models.(Kondru et al. 2017)  Though 
the RT-QuIC assay was developed to rapidly diagnose misfolded prions from human samples, the 
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seed used has been mostly limited to post-mortem samples like brain tissue. Although attempts 
were made to detect PrPD in noninvasive samples from biofluids like blood or saliva, the presence 
of inhibitors that interfere with aggregation limits their utility as diagnostic samples in RT-QuIC 
assays.(Castilla et al. 2005; Henderson et al. 2015; Vieira et al. 2014) More recently, nasal 
brushings from human patients with CJD showed the promising diagnostic application in the 
antemortem diagnosis of prion disease using RT-QuIC(Orru et al. 2014) and PMCA.(Moda et al. 
2014) However, elk nasal brushings did not form a good seed in the RT-QuIC assay for early cases 
since cervid olfactory sensory neurons are not infected until later stages of CWD.(Haley et al. 
2016) In elk, abnormal prions accumulate in the brain, lymph nodes in the head, and spread to 
peripheral lymphoid tissues like RAMALT.(Sigurdson and Aguzzi 2007) In the current study, we 
have evaluated a highly sensitive RT-QuIC assay to detect CWD using RAMALT samples in a 
blinded fashion. IHC of RAMALT, obex, and MRPLN were also performed. We noticed a slight 
increase in the number of positives found in animals with MM polymorphism at codon 132 when 
compared to the ML genotype. This is consistent with previous reports showing higher CWD 
prevalence rate within this genotype.(Haley et al. 2016),(Hamir et al. 2006) Based on the RT-QuIC 
analysis of RAMALT samples, we observed a strong correlation between the RT-QuIC assay and 
IHC of RAMALT sample results, which agree with earlier reports.(Thomsen et al. 2012) 
Therefore, the RT-QuIC assay has the potential to be a useful and complementary diagnostic tool, 
especially given the accessibility of RAMALT samples for CWD diagnosis. Advantages of the 
assay, including the need for only a minor amount of tissue, and simplified sample preparation and 
reading of results, are making it a widely used and versatile technique. The low tissue requirements 
for the RT-QuIC assay also minimizes the amount of trauma experienced by the animal during 
sample collection.(Monello et al. 2013)  
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However, unlike the comparison with RAMALT IHC, we observed a relatively low (~50%) 
sensitivity for RAMALT RT-QuIC assay results when compared with IHC testing of obex and 
MRPLN samples. The low sensitivity is likely due to the variability of PrPD tissue distribution in 
elk (compared to other animals) together with the fact that we only used a small quantity of 
RAMALT tissues in the RT-QuIC assay. Therefore, if a selected sample of RAMALT tissue did 
not contain any PrPD, the RT-QuIC test would be falsely negative for that animal. This could 
potentially be avoided by making homogenate from all the available RAMALT tissue and further 
preparing the seed from this homogenate. Nonetheless, the higher sensitivity of RAMALT RT-
QuIC assay when compared with IHC of RAMALT results demonstrated that the RT-QuIC assay 
is useful for detecting CWD from RAMALT samples. The results of RAMALT RT-QuIC assay 
when compared with the obex grades demonstrates that the animals with higher obex grades (grade 
3 and above) are more likely to be positive on RT-QuIC assay than with the samples with lower 
obex grades, indicating that disease state of the animals is highly variable. 
In summary, we evaluated the diagnostic performance of the RT-QuIC assay for RAMALT 
samples from captive elk in a blinded manner.  Comparing standard IHC and RT-QuIC assays of 
RAMALT samples revealed that these two are well correlated.  
Further improvements in the RT-QuIC seeding assays for cervids could enhance optimal screening 
to achieve greater sensitivity and specificity. This could be achieved using other species of rPrP, 
by optimizing assay conditions, using mouse bioassays and other diagnostic tests like PMCA as 
well. For example, transgenic mice expressing bank vole PrP are highly susceptible to a wide 
variety of prion diseases and rPrP-expressing bank vole PrP (BVrPrP) was able to detect many 
prion diseases including human prions in the RT-QuIC assay.(Orru et al. 2015b) Similarly, BVrPrP 
and cervid rPrP could be important alternate substrates for diagnosing CWD, but this still remains 
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to be tested. We are progressing towards developing an efficient and sensitive RT-QuIC assay for 
ante-mortem samples to screen herds for CWD status, which will assist in deploying rapid control 
and/or preventive measures to better manage CWD. 
Materials and Methods 
Purification of Syrian Hamster recombinant prion protein (SHrPrP) 
SHrPrP encoding a 90-231 amino acid sequence was transformed, expressed in E. coli Rosetta 
cells (EMD Millipore) and purified using previously published methods.(Kondru et al. 2017; West 
Greenlee et al. 2016; Wilham et al. 2010b) In brief, the SHr--PrP expressing Rosetta strain DE2 
of E. coli was inoculated into lysogeny broth (LB) along with auto-induction system1 (EMD 
Millipore) and selection antibiotics. After the cultures were induced overnight, the bacteria were 
harvested after reaching optical density 3 at 600 nm. Inclusion bodies were isolated from these cell 
pellets by treating with 1X Bug Buster (EMD Millipore) followed by 0.1X Bug Buster and 
centrifugation at 13000g for 15 minutes. Then the inclusion bodies were denatured in 8 M 
guanidine hydrochloride (GuHCl) in 100 mM Na Phosphate at pH 8 using OMNI International 
Tissue Homogenizer and rotated for 50 min at RT. Next, the solution with denatured protein was 
centrifuged at 8000 x g for 5 min and the supernatants were added to Ni-NTA superflow resin 
(Qiagen) that had been equilibrated in denaturing buffer [100 mM sodium phosphate (pH 8.0), 10 
mM Tris, 6 M GuHCl]. To allow rPrP to bind to beads, Ni-NTA superflow resin along with 
denatured rPrP was incubated on a rotator for 40 min at RT. Later, the beads were packed in an 
Akta XK26 column at RT. Subsequent steps were carried out under refrigerated conditions for fast 
protein liquid chromatography using Bio-Rad Duoflow. Refolding of rPrP was attained on the 
column by using a gradient from denaturing buffer to refolding buffer (100 mM NaPO4, 10 mM 
Tris [pH 8.0]). After refolding, rPrP was eluted from the column using a gradient from refolding 
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buffer to elution buffer (100 mM NaPO4, 10 mM Tris [pH 8.0], 500 mM imidazole [pH 5.5]) (Fig. 
1A, Top panel). Fractions from the middle of the peak were collected and mixed with pre-chilled 
dialysis buffer (10 mM NaPO4 [pH 5.5]) and dialyzed with three sets of 3.6 L of dialysis buffer. 
Tissue processing and RT-QuIC method 
After collection, samples were stored in -80°C freezer until being tested. RAMALT samples 
measuring 0.3-0.5 cm were dissected from larger rectal biopsies collected 1 cm anterior to the 
mucocutaneous junction (Fig. 3A). This tissue was first homogenized to 10% (w/v) in PBS with 
the help of a Bullet Blender (Next Advance) using 0.5-mm Zirconium oxide beads in 1.5-mL screw 
cap tubes. Conditions for homogenization are three 5-min cycles at a speed setting of 10. Next, the 
homogenates were diluted to 2% (w/v) in PBS.  The samples were then diluted in RT-QuIC 
dilution buffer (0.05% SDS in PBS).(Haley et al. 2014) Next, 5 µL of 0.02% rectal biopsy 
homogenate was added as a seed to 95 μl of RT-QuIC reaction buffer (1X PBS supplemented with 
220 mM NaCl, 10 μM EDTA, 10 μM Thioflavin T (ThT), and 0.1 mg/ml rPrP), in each well of 
96-well plate. We evaluated each rectal biopsy sample (3 replicates per sample) against a blank, 
as well as positive and negative controls in 96-well flat-bottomed (Nunc) plates. Later, the sealed 
plates were analyzed using a Cytation 3 multi-mode plate reader (BioTek) at 42oC with shaking 
(807 rpm, double orbital) and rest cycles that alternated every minute for 24 h. Fluorescence 
readings of ThT were bottom-read at 450-nm excitation and 480-nm emission every 15min using 
a gain setting of 1200. A sample was judged to be positive based on the previously reported 
criterion (Haley et al. 2014) of when the mean of replicate fluorescence readings crossed the 
predetermined threshold (mean fluorescence plus 10 times the standard deviation of known 
negative controls). Each sample ran in quadruplicate with known positive and negative controls. 
After completing data analysis and reporting results, the samples were unblinded to reveal the true 
45 
 
diagnostic status.  Then we calculated the AFR, which is the inverse of the threshold-crossing time 
for each dilution. We used the dilution with the highest AFR to seed all samples.(Henderson et al. 
2015) 
Biophysical and biochemical analyses of rPrP substrate 
To confirm the structure of expressed truncated rPrP, we performed Nuclear Magnetic Resonance 
(NMR) spectroscopy and Circular Dichroism (CD) according to published methods.(Donne et al. 
1997; Zahn et al. 1997) In brief, the CD spectra of the purified protein were recorded on a Jasco 
J-710 Spectropolarimeter using a thermostatted cuvette (Helma) with 1-mm path length. 
Measurements were carried out using a protein diluted in sodium phosphate buffer at 14°C, pH 7, 
yielding a final protein concentration of 8 µM. NMR spectra were recorded using a Bruker Avance 
800 spectrometer. The concentration of protein was 1 mM in sodium phosphate buffer along with 
5% D2O. Samples were prepared in special NMR tubes (Catalog# 897240-0000, Kimble Chase).   
In addition to the biophysical characterization, we tested the purity of rPrP substrate using SDS-
polyacrylamide gel electrophoresis using previously published methods(Kondru et al. 2017). To 
visualize total proteins, Coomassie staining of the gels and Ponceau S staining of membranes were 
used. Western blotting against prion protein used monoclonal antibody 6D11 (Catalog# SIG-
399810, Covance). In brief, proteins were loaded from different fractions and separated on 15% 
SDS-PAGE gels. After transferring the proteins onto nitrocellulose membranes, blots were first 
evaluated with Ponceau S stain (Catalog# P7170, Sigma-Aldrich) to locate the protein since 
Ponceau S does not interfere with polypeptides. The stain was removed by washing membranes in 
distilled water until the background was clean. To block nonspecific binding sites, nitrocellulose 
membranes were blocked with blocking buffer (Li-Cor) for 1 h. Later, the membranes were probed 
with the primary antibody 6D11 for 20 min at RT and washed 5 times with PBS containing 0.05% 
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Tween 20. Then, secondary goat anti-mouse (1:20000, Alexa flour) was used to detect PrPC with 
the Odyssey IR imaging system. 
IHC on the brainstem, RLN, and RAMALT 
The brainstem at the level of the obex, the MRPLN and RAMALT were fixed in 10% buffered 
formalin, processed, sectioned and stained for IHC using the mouse monoclonal primary anti-prion 
antibody F99/97.6.1 (Anti-Prion 99, Ventana Medical Systems) on an automated staining system 
(Ventana Medical Systems). Positive and negative scrapie ovine control tissues were included in 
each staining run and individual tissues were diagnosed as positive or not detected based on the 
presence or absence of characteristic CWD chromogen deposits in the tissue sections. RAMALT 
samples were expected to have a minimum of six lymphoid follicles to be a representative sample 
of the rectal mucosa. A single RAMALT sample (animal 11) had fewer than six follicles and was 
scored as not detected/insufficient follicles (Fig.3B).(Thomsen et al. 2012) 
Obex scoring was used to estimate disease progression in animals whose IHC results for brainstem 
were positive following previously published scoring criteria.(Spraker et al. 2004; Thomsen et al. 
2012) Briefly, an obex score of zero had no detectable positive staining in the obex. An obex score 
of one had limited staining within the vagal nuclei and progressively more staining in the obex 
equated to progressively higher scores. A maximum obex score of four was assigned when 
widespread positive staining occurred in both the gray and white matter throughout the entire 
section of the brainstem. 
Statistical analysis 
Data analysis was performed using Prism 5.0 software (GraphPad). Raw data were analyzed using 
one-way ANOVA, and then Tukey’s post-test was performed to compare different dilutions. 
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Differences with p ≤ 0.05 were considered significantly different, and asterisks were assigned as 
follows: *p ≤ 0.05, **p < 0.01, and ***p < 0.001. ROC curves were drawn using R statistical 
software.  
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Figure 1.  Biochemical and biophysical characterization of purified Syrian Hamster recombinant 
prion protein (SHrPrP) (90-231 residues). (A) The top panel is the elution of rPrP using FPLC. 
The middle panel consists of total protein stain using Ponceau S solution. The bottom panel is the 
Western blot analysis of eluted rPrP using 6D11 antibody. The numbers 1-9 in the middle panel 
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show samples loaded in each well during western blot. Lane 1 represents molecular weight 
standards. Lanes 2-7 represent the protein fractions collected at different steps of protein 
purification. Lanes 5 & 7 (black lines) represent the early and late peak fractions, respectively, 
during elution of protein. Lane 6 (red line) represents the middle of the peak fraction of the eluted 
protein, which is used as a substrate in the RT-QuIC assay. Lane 8 represents the positive control, 
which is also an SHrPrP (90-231), from Dr. Caughey and colleagues, is used as a reference. (B) 
Total protein stain (Ponceau S) and Western blot analysis of pooled SHrPrP (90-231) of purified 
protein and a positive control with the 6D11 antibody. The first lane is molecular weight standards, 
the second lane is purified protein and the third lane is a positive control. (C & D) NMR and CD 
spectroscopy images of SHrPrP (90-231). The blue line represents the SHrPrP (90-231) positive 
control purified at the Caughey lab, and the red line represents SHrPrP (90-231) that we purified. 
(E) AFR in the RT-QuIC assay using reference protein and purified protein as substrates. The blue 







Figure 2. Choosing optimal working dilution and testing RAMALT samples in the RT-QuIC 
assay. (A) Different dilutions of a positive control on the RT-QuIC assay. Each dilution ran in 
triplicate. The 2x10-2 dilution was used for all tested samples. (B) AFR for different dilutions of a 
positive control. The 2x10-2 dilution has more AFR and is significantly different. Asterisks *p ≤ 
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0.05 and ***p < 0.001 added to show the sample concentrations that were significantly different. 
(C) Amplification kinetics of positive and negative elk RAMALT samples along with controls. 
Blue trace represents the RAMALT sample that tested positive in the RT-QuIC assay. (D) AFR of 
RAMALT sample along with a positive control. The blue bar indicates a representative trace of 
















Figure 3. Isolation and immunohistochemical detection of PrPD from RAMALT sample. (A) 
Dissection of recto-anal mucosal (RA) junction to isolate mucosa-associated lymphoid tissue 
(MALT) for RAMALT sample. (B) Immunohistochemistry of RAMALT from elk (Cervus 
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elaphus nelsoni). Note the proteinase-resistant prion staining (red chromogen) distribution within 
the lymphoid follicle located in the lamina propria. Staining was done using a mouse monoclonal 
antibody F99/97.6.1 against epitopes at residues 220-225 of prion protein and developed with 
streptavidin-alkaline phosphatase method. The slides were further counterstained with 
















Figure 4. CWD status of the herd. (A) Stacked bar graph showing infectivity of different tissues 
from MM and ML genotypes at PrP codon 132. Red bars indicate the number of animals that are 
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negative for CWD, while the blue bars indicate CWD-positive animals. (B) ROC curves of 
RAMALT RT-QuIC assay compared against other IHC tests. An AUC >90% indicates high 
accuracy. Among different IHC’s, IHC of RAMALT has highest AUC which is 93.1%, indicating 
RAMALT RT-QuIC assay results were comparable to RAMALT IHC results.    
63 
 
















1 MM P 4 P P P P 
2 MM ND  ND ND ND ND 
3 MM ND  ND ND ND ND 
4 MM ND  ND ND ND ND 
5 MM ND  ND ND ND ND 
6 ML ND  ND ND ND ND 
7 MM ND  ND ND ND ND 
8 ML P 1 ND P P P 
9 MM ND  ND ND ND ND 
10 MM P 3 P P P P 
11 MM ND  ND ND/I ND ND 
12 ML P 1 P ND P ND 
13 MM ND  ND ND ND ND 
14 ML ND  ND ND ND ND 
15 MM ND  ND ND ND ND 
16 MM ND 0 P ND P P 
17 MM P 1 P P P P 
18 ML ND  ND ND ND ND 




Table 1 continued 
20 ML ND  ND ND ND ND 
21 MM ND  ND ND ND ND 
22 MM ND  ND ND ND ND 
23 MM ND 0 P ND P ND 
24 ML ND  ND ND ND ND 
25 MM ND  ND ND ND ND 
26 MM ND  ND ND ND ND 
27 MM ND 0 P ND P ND 
28 ML ND  ND ND ND ND 
29 MM P 3 P P P P 
30 MM P 2 P P P P 
31 MM ND  ND ND ND ND 
32 MM P 3 P P P P 
33 MM ND  ND ND ND ND 
34 MM ND  ND ND ND ND 
35 ML ND  ND ND ND ND 
36 MM ND  ND ND ND ND 
37 MM ND  ND ND ND ND 
38 MM ND  ND ND ND ND 
39 ML ND  ND ND ND ND 
40 MM ND  ND ND ND ND 
41 MM ND  ND ND ND ND 
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Table 1 continued 
42 ML ND  ND ND ND ND 
43 ML P 1 ND ND P ND 
44 ML ND  ND ND ND ND 
45 MM ND  ND ND ND ND 
46 MM ND 0 P ND P ND 
47 MM P 2 P ND P ND 
48 MM P 1 ND ND P ND 
49 ML ND  ND ND ND ND 
50 MM P 2 P P P ND 
51 MM ND 0 P ND P ND 
52 ML ND  ND ND ND ND 
53 MM P 1 P ND P ND 
54 MM P 2 P ND P ND 
55 ML ND  ND ND ND ND 
56 MM P 3 P P P P 
57 ML P 3 P P P P 
58 MM ND  ND ND ND ND 
59 MM ND  ND ND ND ND 
60 MM ND  ND ND ND ND 
61 MM P 3 P P P P 
62 MM ND  ND ND ND ND 
63 MM P 1 P P P P 
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Table 1 continued 
64 MM ND  ND ND ND P 
65 MM P 1 P ND P ND 
66 MM ND  ND ND ND P 
67 MM ND  ND ND ND ND 







1- 8;  
2- 4; 











The number of animals testing positive and negative for CWD were tabulated. Out of 69 samples, 
genotyping was available for only 68 animals. IHC of MRPLN detected the highest number of 
positives followed by IHC of obex, RT-QuIC assay of RAMALT and IHC of RAMALT. Samples 
that were positive in IHC of obex were scored as 0, 1, 2, 3 & 4 based on the distribution and extent 
of PrPD in the brain. Obex score of zero represents elk that were MRPLN positive but had no 
staining in the obex, and a score of one represents the minimal distribution of PrPD around vagal 
nuclei with higher scores indicating more extensive distributions. A score of 4 represents 
widespread distribution in the gray and white matter of the brainstem. P = positive; ND = not 
detected, ND/I= not detected, insufficient follicles.  
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Table 2: Correlation between various tests. 
 
 
Correlation between different diagnostic tests with upper and lower 95% confidence intervals. 
When comparing all detection procedures, the outcome of the RT-QuIC analysis of RAMALT was 
highly correlated to those of IHC results demonstrating the efficacy of RT-QuIC assay for CWD 







Variable by Variable Correlation Lower 95% Upper 95% 
RAMALT RT-QuIC IHC of RAMALT 0.8144 0.7156 0.8812 
IHC of obex IHC of RAMALT 0.7443 0.6162 0.8341 
IHC of obex RAMALT RT-QuIC 0.5764 0.3934 0.7155 
IHC of MRPLN IHC of RAMALT 0.5886 0.4089 0.7244 
IHC of MRPLN RAMALT RT-QuIC 0.5054 0.3053 0.6628 
IHC of MRPLN IHC of obex 0.6922 0.5447 0.7981 
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Aggregated proteins are emerging as a hallmark pathological feature of many neurodegenerative 
diseases including Parkinson’s, Alzheimer’s and Huntington’s diseases as well as classical prion 
diseases. We have previously reported that divalent metals can interact with alpha-synuclein and 
prion proteins to alter metal neurotoxicity. Although manganese (Mn) has been reported to interact 
with prion protein, whether Mn plays a direct role in template-driven conversion, leading to 
enhanced prion protein aggregation remains to be investigated. In the current study, we address 
this question by adopting a real-time quaking-induced conversion (RT-QuIC) assay to characterize 
the role of Mn in the aggregation and seeding process of infectious scrapie prion protein. We first 
quantified prion seeding activity in the presence or absence of various concentrations of Mn (10 
μM - 10 mM) treated to various cell densities of Cath. A-differentiated (CAD5) neuronal cells 
harboring RML mouse scrapie prions [CAD5 (+)] and uninfected CAD5 [CAD5 (-)] cells. We 
found that Mn affected the scrapie prion seeding activity in [CAD5 (+)] cells but not for the [CAD5 
(-)] cells. Other metals such as copper (Cu), magnesium (Mg) and nickel (Ni) were not as effective 
as Mn in the seeding activity of prions, supporting a specificity for Mn. To further translate the 
biological implications of our cell-based studies, we adapted a low-dose exposure paradigm to an 
organotypic brain slice culture model of prion disease. Mn-promoted seeding kinetics of scrapie 
prion in this novel ex-vivo prion model, further validating the ability of Mn accelerate prion seeding 
activity in brain tissues. Collectively, our study demonstrates that Mn amplifies template-driven 
prion protein seeding activity to enhance the protein aggregation process and may have 
implications for the pathogenesis of other protein-misfolding diseases, such as Parkinson’s disease 





Uninfected Cath. A-differentiated [CAD5 (-)] and RML Scrapie infected CAD5 [CAD5 (+)] cells, 
RT-QuIC assay, protein aggregation rate, manganese (Mn), & slice cultures. 
Introduction  
Prion diseases are transmissible spongiform encephalopathies consists of mainly Creutzfeldt-
Jakob disease (CJD) and kuru in humans(Siedler and Malamud 1963), scrapie in sheep(Bolton et 
al. 1982), bovine spongiform encephalopathy in cattle(Hope et al. 1989), and chronic wasting 
disease in cervids(Williams and Young 1982). The disease is characterized by the conversion of 
normal cellular prion protein (PrPC) into misfolded prion protein (PrPSc) and this PrPSc is thought 
to serve as a template for further catalytic conversion of PrPC and causes damage(Prusiner 1982). 
PrPSc remains to be the main pathological event in all prion diseases that are characterized by a 
very long incubation period, neurobehavioral changes and spongiform vacuolation of central 
nervous system(Aguzzi and Polymenidou 2004; Collinge 2005; Prusiner 1998b; Weissmann 
2004). PrPC is a globular protein and anchors to the outer surface of the cell membrane with a 
glycosyl-phosphatidyl-inositol (GPI)(Stahl et al. 1992). It consists of the alpha-helix-rich region 
towards the C-terminal and octapeptide repeat regions at the N-terminus. During the conversion 
of PrPC into PrPSc, the alpha-helix-rich region will be converted into beta-sheets that gain protease 
resistance(Miura et al. 1996). The exact physiological function of PrPC is not known but it is known 
to be involved in myelin maintenance, cell signaling, apoptosis, metal homeostasis, and oxidative 
stress(Anantharam et al. 2008; Choi et al. 2010; Choi et al. 2007; Harischandra et al. 2014).  
It has been known that PrPC is a metalloprotein having high binding affinity for divalent metals 
like copper (Cu), manganese (Mn) and zinc (Zn). These metal binding sites play an important role 
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in the pathogenesis of prion diseases(Brown 2009; Hornshaw et al. 1995). Moreover, altered levels 
of Mn was observed in the blood and brains of humans, mice, and cattle infected with prion 
diseases(Brown 2009). Increasing the levels of Mn caused the enhanced survival and 
transmissibility of prion protein in soil and cell culture models of prion diseases(Davies and Brown 
2009). We also reported the effect of Mn in the oxidative stress, proteasome and mitochondrial 
functions using cell culture models of prion diseases and found the upregulation of cellular prion 
protein during Mn exposure in neuronal cells(Choi et al. 2010; Choi et al. 2007). Binding of Mn 
to the PrPC increased the polymerization and aggregation abilities thus leading to increased 
protease resistance(Abdelraheim et al. 2006; Giese et al. 2004). Using isothermal titration 
calorimetry, scientists have proven that PrPC has Mn binding sites especially at His-95, “fifth site” 
and triggers changes associated with prion disease(Brazier et al. 2008). Despite these evidences of 
Mn binding to the prion protein, it is unclear whether it has a role in the template driven conversion 
of the prion protein. In the present study, we examined the role of Mn in the seeded conversion of 
prion protein using a Real-Time Quaking Induced Conversion (RT-QuIC) assay in the persistent 
RML scrapie-infected Cath. A-differentiated [CAD5 (+)], uninfected neuronal [CAD5(-)] cells 
and the organotypic slice culture models. From herein, RML scrapie-infected and uninfected cells 
are called as CAD5 (+) and CAD5 (-) cells, respectively. We also observed the effect of Mn and 
other metals on Syrian Hamster recombinant prion protein (SHrPrP) (residues 90-231) in the in-
vitro environment and noticed the ability of Mn to convert the SHrPrP (90-231) into aggregates 
thereby causing enhanced Thioflavin-T (ThT) fluorescence but neither Mn nor SHrPrP (90-231) 
alone does not have any enhanced fluorescence in the RT-QuIC assay. Along with these findings, 
first time, we were able to detect the amyloid seeding activity from a broad range of CAD5 (+) 
cell densities. There has been evidence that exosomes derived from the prion-infected cells are 
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infectious(Fevrier et al. 2004). To further test the seeding ability of the exosomes, we have isolated 
the exosomes from the CAD5 (+) and CAD5 (-) cells and noticed the amyloid seeding activity 
only from the exosomes of CAD5 (+) cells. Collectively, our findings suggest that Mn increases 
the templated conversion of prion protein in in-vitro, cell culture and slice culture models of prion 
diseases and exosomes isolated from the prion-infected cells have the seeding ability.  
Results 
Manganese induces a template-driven conversion of prion protein to aggregates 
To investigate the role of manganese in prion protein aggregation, we tested different 
concentrations of manganese (Mn), 0.1uM, 10uM, 1uM, 100uM, 1mM, and 10mM in the RT-
QuIC assay using SHrPrP (90-231) as a substrate. Among different concentrations of Mn used, 
10mM and 1mM concentrations were able to initiate the temple driven conversion of normal 
SHrPrP (90-231) into aggregated form and can see the Thioflavin T (ThT) fluorescence intensity 
measurement. (Fig. 1A). Protein aggregation rate (PAR) for the ThT fluorescence can be measured 
by taking the inverse of time to cross the threshold fluorescence which can be derived by taking 
the average of first ten reactions of the blank controls in the assay. PAR for 10mM and 1mM Mn 
concentrations is significantly different from the other concentrations of Mn (Fig. 1B). No 
spontaneous fluorescence was observed in the wells having only Mn (Fig. 1C) indicating that Mn 
is not interfering with the ThT signal. To further validate the Mn-dependent conversion of SHrPrP 
(90-231), we aggregated the recombinant prion protein i.e SHrPrP (90-231) with 10 µM, 100 µM 
and 1 mM concentrations of Mn at 37oC for 3, 12 and 24 hours in a thermal cycler and observed 
the significant enhancement in ThT fluorescence after 24 hours of incubation with 100 µM and 1 
mM of Mn concentrations compared to SHrPrP (90-231) alone (Fig. 1D, 1E & 1F). 
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Identification of Mn associated aggregates  
The aggregates formed during incubation of SHrPrP (90-231) and various concentrations of Mn 
were analyzed using a matrix-assisted laser desorption ionization-time of flight mass spectrometry 
(MALDI-TOF MS). With the help of MALDI-TOF MS the high mass molecules i.e the aggregates 
of SHrPrP (90-231) have detected in the Mn treated samples but not in the samples having only 
SHrPrP 90-231 (Fig. 2A). Well, area scan also reveals the increased deposition of prion aggregates 
along with an increase in the concentrations of Mn indicating the key role of Mn in augmenting 
templated conversion of prion protein and no prion aggregates were detected with only the SHrPrP 
90-231 wells (Fig. 2B). 
Detection of prion seeding activity from CAD5 (+) cells 
Before testing the Mn neurotoxicity in prion cell culture models, we tested the optimal 
concentration of CAD5 (+) cells required to initiate the template driven conversion of prion protein 
in the RT-QuIC assay. Cells in different densities were seeded in the 96-well plate using serum-
free media. Later SHrPrP (90-231) is added to each well after removing the serum-free media and 
observed for ThT amplification kinetics. We observed an increase in ThT intensity from 5000 cells 
to all the way up to 30 individual cells in the assay (Fig. 3A) but no signal was detected in CAD5(-
) cells (Fig. 3B). We noticed an increase in the PAR with a decrease in the CAD5 (+) cell density 
indicating that the optimal concentration of cells is essential for seeding prion like ability in the 
RT-QuIC assay (Fig. 3C). We compared the bright field image of cell density in each well with 
the RT-QuIC amplification plot for easy understanding of how well the RT-QuIC assay is 
detecting the prion seeding activity even from a very low number of CAD5 (+) cells indicating the 
potential for detecting fewer amounts of misfolded prions (Fig. 3D).  
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Prion seeding activity from exosomes isolated from the CAD5 (+) cells                                                  
To elucidate the role of exosomes in prion transmission, we isolated the exosomes from the CAD5 
(+) and CAD5 (-) cells and characterized the size using electron microscopy (Fig. 4A). Vesicles 
isolated from the CAD5 (+) were able to show the prion seeding ability in the RT-QuIC assay but 
no seeding activity was detected with the vesicles isolated from CAD5 (-) cells (Fig. 4B). From 
these studies, it is evident that prion seeding ability can be observed in CAD5 (+) cells and 
exosomes from CAD5(+) cells. 
Enhanced amyloid seeding activity from Mn treated CAD5 (+) cells  
The role of Mn in prion protein misfolding was evaluated in the prion cell culture models. we 
treated the CAD5 (+) and CAD5 (-) cells with 1 µM, 10 µM, 100 µM, and 500 µM concentrations 
of Mn and tested the cell lysates in the RT-QuIC assay for prion seeding activity. The seeding 
activity was observed with CAD5 (+) cells and further enhancement in ThT fluorescence and early 
amplification was observed with Mn treated CAD5 (+) cells. Whereas, in CAD5 (-) cells, Mn 
treatment did not cause any change in the seeding activity over the entire duration of RT-QuIC 
assay (Fig.5).  
Effect of cell density on Mn-induced amyloid formation in the RT-QuIC assay 
After assessing the cell density required for the RT-QuIC assay, we have chosen 312, 625 and 
1250 cells for testing 100 µM of Mn concentration. From the amplification plots, it is evident that 
adding Mn to the CAD5 (+) cells caused the early aggregation and increased seeding ability 
compared to the untreated CAD5 (+) cells (Fig. 6A, B, & C).  Significantly higher prion aggregates 
were deposited for 100 µM Mn treated cells compared to the CAD5 (+) cells without Mn treatment 
in various cell densities tested in the RT-QuIC assay (Fig. 6D, E, & F). From these results, it is 
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evident that 100µM Mn is causing an increase in seeding ability of CAD5 (+) cells and exposure 
to Mn is responsible for early onset of prion protein aggregation. No increase in ThT fluorescence 
was observed with the CAD5 (-) cells or wells having only SHrPrP 90-231 in the RT-QuIC assay. 
Chronic low dose Mn exposure promotes early prion amplification in slice cultures 
Recent studies from our lab showed that the cerebellar slices from 9-12-day old mouse pups can 
be treated with RML or normal brain homogenates and cultured for several weeks. These slices 
can become infected and increase in ThT fluorescence kinetics can be measured using RT-QuIC 
assay(Kondru et al. 2017). In a similar manner, we treated the RML infected slices with a chronic 
low dose, the 10µM concentration of Mn by adding to slice culture media. Along with Mn, we 
also tested other metals like Nickel (Ni), Copper (Cu), and Zinc (Zn) at low 10µM concentrations 
but Mn treated RML infected slices caused remarkable early aggregation in the RT-QuIC assay 
compared to infected slices. Next to Mn, we observed an increase in aggregation with Ni treatment 
to RML infected slices. Cu or Zn treatments caused no amplification at all over the entire period 
of the reaction (Fig. 7A). By plotting the PAR’s for RML infected and treated with Mn or Ni slices, 
it is evident that Mn treatment caused a significant increase in the deposition of prion aggregates 
compared to other treatments (Fig. 7B). 
Discussion 
Metal neurotoxicity is known to play a key role in neurodegenerative conditions including 
protein misfolding and oxidative stress. Protein misfolding is a main pathological event occurs in 
several neurodegenerative diseases like a prion, Parkinson’s and Alzheimer’s diseases. There has 
been an evidence that prion protein is a metal binding protein and can bind to metals like 
manganese (Mn) and can alter the pathogenesis of prion diseases. Increased levels of Mn in the 
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brains and blood of humans and animals affected with prion diseases suggest that Mn has a critical 
role in establishing prion pathology(Hesketh et al. 2008). From the previous publications of our 
lab, it is evident that normal prion protein protects the neuronal cells against Mn-induced oxidative 
stress, mitochondrial dysfunction, and apoptosis(Choi et al. 2007). So, in the present study, we 
investigated the role of Mn in the template driven conversion of PrPC into PrPSc thereby promoting 
the aggregation and pathogenesis in prion diseases.  
Our results demonstrated that Mn at 10- and 1-mM concentrations can cause the conversion of 
SHrPrP 90-231 into misfolded prion protein and increased the ThT fluorescence in the RT-QuIC 
assay. SHrPrP 90-231or Mn alone did not cause any increase in the ThT fluorescence. Aggregation 
of SHrPrP 90-231 along with various concentrations of Mn for 24 hours increased the ThT 
fluorescence in the ThT assay indicating the presence of aggregates (Fig. 1 & 2). To confirm the 
observed findings, we adopted cell and slice culture models of prion diseases using RT-QuIC assay 
as a read-out for detecting prion aggregates. For the first time, we were able to detect the prion 
seeding activity from a very low number of CDA5 (+) cells (from 30 cells) and no seeding activity 
was detected in the uninfected cells even after treating with Mn (Fig.3 & 5). After adapting the 
RT-QuIC assay with the cells, we treated the cells with 100 µM Mn to determine the role of Mn 
in the seeding activity. Mn caused the early templated conversion of recombinant prion protein 
into aggregated prion protein in the CAD5 (+) cells (Fig. 6). Later we tested the Mn role in the 
organotypic slice cultures infected with RML Scrapie and normal brain homogenates. We noticed 
the early amplification in the RML scrapie slices treated with Mn compared to scrapie-infected 
slices in agreeing with the cell culture data. We also tested the seeding activity from exosomes 
released by CAD5 (+) cells and no seeding activity was detected in the exosomes from the CAD5 
(-) cells (Fig. 4), which is consistent with the previous findings (Fevrier et al. 2004).  
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In summary, we have established a highly sensitive RT-QuIC assay for the cell culture models 
of prions and tested the role of Mn in the templated conversion of prion protein (Fig. 8). Our cell 
culture coupled RT-QuIC assay (Fig. 3) can able to screen a large number of anti-prion compounds 
and thereby improving the translational impact in therapeutics. We also tested the role of other 
metals like Cu, Mg, and Ni in the templated conversion of recombinant prion protein but none of 
these metals have caused the increased aggregation like Mn (Supplementary Fig. 1). Furthermore, 
cell culture coupled RT-QuIC assay can be adapted to other neurodegenerative disorders having 
the principle of templated driven conversion of monomer into aggregates to produce pathogenicity 
like in Parkinson’s, Alzheimer’s and other protein misfolding diseases. 
Materials and methods 
Persistent propagation of prions in cell culture models 
The Cath.a-differentiated, CAD5 cell line used for the experiments is a generous gift of Dr. Charles 
Weismann. These CAD5 cells were persistently infected with Rocky Mountain Lab (RML) mouse 
scrapie strain. Procedure to generate CAD5 infectious prion cell cultures were described elsewhere 
(Mahal et al. 2007). Uninfected and RML scrapie-infected cells were maintained at 5% CO2 and 
37oC in a humidified atmosphere with Opti-MEM as a growth media including 50 units of 
penicillin, 50 µg/ml of streptomycin and 10% fetal bovine serum (Invitrogen). Cells were screened 
to check the retention of RML scrapie infection before testing in the experiments (Supplementary 
Fig. 2).  
Purification of Syrian Hamster recombinant prion protein 
Syrian Hamster recombinant prion protein with amino acid residues 90-231 was expressed and 
purified as described previously(Kondru et al. 2017; Manne et al. 2017). In brief, plasmids 
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encoding N-histidine-tagged 90-231 prion protein in pET vector (EMD Biosciences) were 
transformed into E. Coli RosettaTM2 (DE3) cells with kanamycin and chloramphenicol as 
selective antibiotics. Later bacteria were induced with Overnight ExpressTM Autoinduction System 
1 (EMD Millipore Cat No. 71300) to express the protein using mini-cultures as a startup material. 
After expression, bacteria were harvested at 4000 x g for 20 minutes and then lysed to isolate 
inclusion bodies with Bug Buster Master (EMD Millipore) Mix. The protein present in the 
inclusion bodies were denatured using 8 M guanidine hydrochloride (GuHCl) in 100 mM Na 
Phosphate buffer at pH 8 using an OMNI international Tissue Homogenizer and then incubated 
for 50 minutes by continuous rotation. The denatured protein was centrifuged at 8000 x g for 5 
minutes and the supernatant was equilibrated with the nickel-nitriloacetic acid (Ni-NTA) resin 
(Qiagen Cat No. 30430) for another 50 minutes by continuous rotation. Later the beads were 
packed in an Akta #XK26 column and purified with fast pressure liquid chromatography using a 
Bio-Rad Duoflow at 4oc. On-column refolding of SHrPrP was done using a gradient from 
denaturing to refolding buffer (100 mM NaPO4, 10 mM Tris [pH 8]. Finally, elution of SHrPrP 
was done with a gradient from refolding buffer to elution buffer (100 mM NaPO4, 10 mM Tris, 
500 mM imidazole [pH 5.5]). Dialysis of the SHrPrP was carried out in three sets of 3.6 L pre-
chilled dialysis buffer (10 mM NaPO4 [pH 5.5]), the concentration of protein was determined by 
measuring the absorbance at 280nm using a nanodrop and stored at -80oC at 1 mg/ml 
concentrations. Every batch of protein was tested with western blot analysis and RT-QuIC assay 
prior to use.  
RT-QuIC protocol 
RT-QuIC was conducted as described previously (Kondru et al. 2017; Manne et al. 2017; Orru et 
al. 2014) with some modifications. Unless otherwise specified, RT-QuIC reaction mixture consists 
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of final concentrations of 350 mM NaCl, 10 µM EDTA, 10 µM ThT and 0.1 mg/ml of SHrPrP 90-
231 as a substrate to each well of 96-well plate. For the cell-based RT-QuIC assay, Nalgene Nunc 
96-well black bottom plates were seeded with various densities of CAD5 (+) and CAD5 (-) cells 
from 20 thousand to 30 individual cells using Opti-MEM without fetal bovine calf serum as a 
growth media. Cells were regularly checked using a phase contrast microscopy. After 2-3 days of 
culturing cells in 96-well plate, growth media was removed and washed with sterile PBS two times 
carefully. Later 100 µl of RT-QuIC reaction mixture was added to each well of 96-well plate. For 
Mn treatments to the CAD5 cells, cell densities of 1250, 625, and 312 cells were treated with 100 
µM Mn, the day prior to test in the RT-QuIC assay and tested in the assay after adding 100 µl of 
the reaction mixture. Plates were sealed and analyzed using a CLARIO star (BMG) at 42oC with 
an alternate 1-min shake (double orbital) and rest cycles and ThT fluorescence readings were taken 
at 450 nm excitation and 480 nm emission for every 30 minutes and data analysis was done using 
MARS version 5.2. R8 followed by data export into Microsoft Excel or GraphPad Prism 7 for 
further analysis. For Invitro RT-QuIC assay, each well of 96-well plate is loaded with 95 µl of RT-
QuIC reaction mixture and 5 µl of various concentrations of Mn, Cu, Mg and Ni were added and 
taken the readings with the cell-based RT-QuIC assay. For RT-QuIC assay using exosomes, after 
isolating exosomes from the cell culture media, resuspended in sterile PBS. 5 µl of the resuspended 
vesicles is added as a seed to the 95 µl of the reaction mixture and fluorescence readings were 
taken. Various dilutions of the cell lysates of CAD5 (+) and CAD5 (-) were also used as a seed in 
the RT-QuIC assay. For this, harvested the cells and slices in sterile PBS and centrifuged at 4000 
x g for 5 minutes to remove dead cells and again resuspended in sterile PBS. 10-fold and 100-fold 
dilutions of resuspended cells lysates were used as seed in the RT-QuIC assay to detect the prion 
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seeding activity. For slice culture lysates as a seed, harvested the slices in sterile PBS and loaded 
5 µl of lysate in the RT-QuIC assay. 
Thioflavin T (ThT) assay 
Mn-induced aggregates of SHrPrP (90-231) were analyzed with ThT assay done in a 384-well 
plate. 95 µl of 25 µM ThT was loaded into each well and 2.5 µl of in-vitro generated fibrils were 
added then mixed up and down using a pipette. After two minutes of incubation of plate at room 
temperature, fluorescence readings were taken at excitation and emission of 450 nm and 480 nm 
respectively.   
Exosomes isolation 
Exosomes were isolated as described previously. In brief, cell culture media having 10% exosome 
depleted FBS from CAD5 (+) and CAD5 (-) cells were collected and centrifuged at 300 x g for 10 
minutes to remove the dead cells and centrifuged again at 10,000 x g for 15 minutes to remove the 
cell debris. Later, media was filtered through a 0.22-µm syringe filter and subjected to 
ultracentrifugation at 100,000 x g for 90 minutes using a Beckman Optima L-100 XP 
ultracentrifuge. The resulting pellet was washed with cold and sterile PBS and again centrifuged 
at 100,000 x g for 90 minutes using a Beckman Optima MAX ultracentrifuge. Finally, the resulting 
pellet was resuspended in 100 µl of sterile PBS and used as a seed in the RT-QuIC assay.   
Transmission electron microscopy (TEM) 
Exosomes resuspended in sterile PBS were characterized with the TEM. 20 µl of resuspended 
sample was mixed with 2% uranyl acetate and incubated for 5 minutes. 5 µl of sample was applied 
to carbon-coated copper grids and images were taken with JEOL 2100 200-kV scanning 
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transmission electron microscope (STEM) operated ta 80 kV. The analysis was done using a 
Thermo Fisher Noran System 6 elemental analysis system.   
Slice culture protocol 
All the experiments with animals were done by following the protocols approved by Iowa State 
University’s Institutional Animal Care and Use Committee (IACUC). Slice cultures were done as 
described previously(Falsig and Aguzzi 2008; Kondru et al. 2017). Briefly, cerebellar brain slices 
were prepared from 9- to 12-day-old pups of wild-type mouse using a microtome 
(CompresstomeTM VF-300, Precisionary Instruments). Cerebellum was placed in a 
CompresstomeTM specimen tube in a sagittal plane and filled with a 2% low-melting-point agarose. 
The chilling block was applied around the specimen tube for easy solidification of agar. 350-µm 
slices were collected in a slicing reservoir filled with ice-cold Gey’s balanced salt solution having 
kynurenic acid (GBSSK). The composition of GBSS is final concentrations of 8 g NaCl, 0.37 g 
KCl, 0.12 g Na2HPO4, 0.22 g CaCl2 ∙ 2H2O, 0.09 g KH2PO4, 0.07 g MgSO4 ∙ 7H2O, 0.210 g 
MgCl2 ∙ 6H2O, 0.227 g NaHCO3 per liter. Slices from the reservoir were transferred to a new plate 
having GBSSK and added normal brain homogenate or Rocky Mountain Labs scrapie brain 
homogenate (RML Scrapie) at concentrations of 100 µg/ml, diluted in 1 mL of GBSSK. After 1hr 
of incubation with the inoculum, slices were washed twice with an ice-cold GBSSK and transferred 
to Millicell 6-well. Media was changed every other day and after 2 weeks slices were treated with 
chronic low doses of Mn, Cu, and Ni at 10 µM concentrations added to the culture media. After 4 
weeks in culture, slices were harvested by washing twice in 2 ml of ice-cold PBS. Different 
dilutions of slice culture lysates were used as a seed in the RT-QuIC assay.  
Proteinase K (PK) digestion and Immunoblotting 
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Western blot analysis and limited proteolysis were done as described previously with few 
modifications(Choi et al. 2010; Harischandra et al. 2014; Kondru et al. 2017; Martin et al. 2011). 
In brief, CAD5 (+) and CAD5 (-) cells were washed with ice-cold PBS and then lysed with a lysis 
buffer (150mM NaCl, 50 mM Tris-HCl pH 7.4, 5 mM EDTA, 2% Triton X, and 2% sodium 
deoxycholate) for 30 minutes. Protein concentrations were estimated using a Bradford assay and 
25 µg/ml of Proteinase-K was used for 2 mg of protein present in cell lysates and incubated for 30 
minutes at 37oC. The action of PK was stopped by boiling the samples for 10 minutes. The proteins 
were separated using SDS-PAGE on 15% polyacrylamide gel and later proteins were transferred 
on to a nitrocellulose membrane and blocked with LI-COR blocking buffer for an hour and then 
probed with primary followed by secondary antibodies to visualize the bands. POM1 PrP antibody 
(1:5000, Prionatis AG) was used as a primary antibody, incubated overnight at 4oC and washed 
with 0.1% Tween in 1X PBS three times. Later incubated with a secondary antibody and images 
were captured with an Odyssey IR imaging (LI-COR) system and analyzed using Odyssey 2.0 
software.  
MALDI-TOF MS 
MALDI-TOF MS analysis was done using Shimadzu AXIMA Confidence MALDI TOF Mass 
Spectrometer. High molecular weight aggregates were analyzed using a linear mode of the 
instrument. In brief, 10 µl of the sample without SDS is loaded onto the matrix grid. Once the 
sample is dried, the laser beam coming from the instrument will analyze the molecular weights of 
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Figure. 1 Mn driven prion protein aggregation. A. 5 µl of various concentrations of Mn (0.1 µM 
to 10 mM) were added to the 95 µl RT-QuIC reaction mixture having final concentrations of 350 
mM NaCl, 10 µM EDTA, 10 µM ThT and 0.1 mg/ml of SHrPrP 90-231 as a substrate and taken 
the fluorescence readings. 10- and 1-mM concentrations of Mn were able to initiate the template 
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driven conversion of the prion protein. B. PAR’s for the various concentrations of Mn tested in the 
RT-QuIC assay. C. No spontaneous amplification was detected in the wells provided with only 
Mn without recombinant prion protein. D, E & F represents the deposition of prion aggregates 
using ThT assay after incubation of SHrPrP 90-231 with various concentrations of Mn at 37oC for 
3h, 12h & 24h respectively. Each trace represents the average of 8 replicates. 
 
 
Figure. 2 Mn-dependent deposition of prion aggregates. A. Representative MALDI-TOF mass 
spectrum indicating the presence of high molecular weight aggregates (shown with downward 
arrows) in the samples of SHrPrP 90-231 incubated with Mn for 24 hrs. No aggregates were 
detected in samples having only SHrPrP 90-231. B. Well, area scan showing the accumulation of 










Figure. 3 Cell culture coupled RT-QuIC assay. A & B. ThT fluorescence with various cell 
densities of CAD5 (+) and CAD5 (-) cells in the RT-QuIC assay. Cells were grown in 96-well 
plate with serum-free media for two days. Later media was taken off, washed the wells with 100 
µl of sterile PBS twice and tested in the RT-QuIC assay after adding reaction mixture. CAD5 (+) 
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cells showed the amplification from 5000 cells to 30 cells and no amplification was detected in 
CAD5 (-) cells.  C. PAR’s of various cell densities of CAD5 (+) cells. D. Comparison of bright 
field images of various cells densities and the respective amplification curves in the RT-QuIC 
assay. Each trace represents the average of 8 replicates. 
 
 
Figure. 4 Release of PrPSc in association with exosomes from CAD5 (+) cells. A. Electron 
micrograph picture of exosome-like vesicles isolated from the cell culture models. Scale bar is 
100nm. B. Prion seeding activity was detected from the exosomes isolated from CAD5 (+) cells 
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using the RT-QuIC assay (shown in red color) not from the exosomes isolated from CAD5 (-) 





Figure. 5 Role of Mn in template driven prion protein conversion in cell culture models. Both 
CAD5 (+) and CAD5 (-) cells were treated with 1 µM, 10 µM, 100 µM, and 500 µM concentrations 
of Mn. Prion seeding activity was noticed with only CAD5 (+) cells and enhanced activity was 









Figure. 6 Effect of cell density in prion protein conversion using cell culture models. A, B & C. 
Early amplification associated with CAD5 (+) cells treated with 100 µM Mn (red trace) compared 
to untreated CAD5 (+) cells (blue trace) having cell densities of 312, 625 and 1250 cells 
respectively. D, E & F. PAR’s of 100 µM Mn treated cells in comparison with CAD5 (+) cells 





Figure. 7 Testing the role of Mn using organotypic slice culture models. A. 5 ng of slice culture 
homogenate was used as a seed in 95 µl of RT-QuIC reaction mixture having final concentrations 
of 350 mM NaCl, 10 µM EDTA, 10 µM ThT and 0.1 mg/ml of SHrPrP as a substrate. RML 
infected slices treated with Mn (shown in red color) had early amplification compared to untreated 
RML infected slices (shown in green color). B. PAR’s of RML infected slice and Mn treated RML 
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infected slices. A significant difference in the amyloid deposition was observed with Mn treatment 
in slice culture models. 
Figure. 8 Schematic representation of Mn-induced prion protein aggregation. Mn interacts with 
the SHrPrP 90-231 and tends to aggregate and provides a template for further conversion of 
SHrPrP into aggregates and increased ThT fluorescence was observed with the RT-QuIC assay. 
The RT-QuIC assay was performed in a 96-well plate with alternate cycles of shake and rest and 
fluorescence readings were taken for every 30 minutes at an excitation of 450nm and emission of 
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Abstract 
Background: Manganese (Mn) neurotoxicity is well documented in individuals occupationally 
exposed to welding fumes, but no blood-based biomarkers are available for Mn poisoning except 
for expensive imaging techniques, like brain MRI. 
Objective: We identified the biomarker role of  α-Synuclein (αSyn) aggregates and other small 
RNAs associated with the exosomes isolated from the serum and plasma samples of a population 
exposed to welding fumes and age-matched controls.  
Methods: We optimized an ultra-sensitive and specific real-time quaking induced conversion (RT-
QuIC) assay to detect the αSyn aggregates in Mn-exposed individuals and determined the 
diagnostic utility of the RT-QuIC assay using exosomes isolated from a blinded cohort of serum 
and plasma samples. We also performed next-generation sequencing of serum exosomes to 
identify several small RNAs, such as miRNAs, piRNAs and tRNAs that may contribute to Mn 
neurotoxicity. 
Results: We could differentiate the welders from controls with >95% sensitivity and specificity 
by detecting the exosome associated αSyn aggregates using the RT-QuIC assay. RNA-sequencing 
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analysis identified differential expression of several small RNAs in welder population compared 
to controls revealing the potential biomarker role of small RNAs. 
Conclusion: Collectively, our findings demonstrate the discovering of exosome-associated αSyn-
based biomarkers and small RNA biomarkers.  
Introduction 
Manganese is an essential element found in all body tissues as it is essential for many ubiquitous 
enzymatic reactions, including synthesis of amino acids, lipids, proteins, and carbohydrates. 
Despite of its vital role in several enzymatic reactions, chronic exposure to Mn may leads to a 
sever neurodegenerative condition resembling Parkinson’s disease (PD), known as manganism or 
Mn-induced parkinsonism (Aschner et al. 2009; Guilarte 2010; Huang et al. 1989; Mergler et al. 
1994). Manganism shares clinical signs with Parkinson’s disease (PD) in gait abnormalities but 
does not present as a clinical PD due to lack of nigrostriatal dopaminergic neuron damage and 
response to levodopa treatment. First case of manganism was reported in 1837, in workers due to 
inhalation of  high levels of manganese oxide while grinding the manganese ores (Couper 1837). 
Later, an outbreak of clinical cases of manganism was reported due to massive exposure to Mn in 
workers of Chilean Mn mine (Rodier 1955). Welders, miners, alloy manufacturers and dry cell 
battery producers are therefore at an increased risk for Mn-induced Parkinsonism (Antonini et al. 
2006; Chang et al. 2013; Kim et al. 1999; Racette et al. 2012b), and a range of neuropsychological 
and neurological sequelae has been documented in exposed workers. Mn preferentially 
accumulates in the basal ganglia, especially in the globus pallidus area, but the exact pathogenic 
mechanism by which Mn exerts its neurotoxic effects remains elusive (Mena et al. 1967; Racette 
et al. 2012a; Roth 2009). Based on the results from the study on non-human primates, it was 
evident that movement abnormalities associated with chronic exposure to Mn were due to the 
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inability of dopaminergic neurons to release dopamine (Guilarte et al. 2006). Recommended 
threshold limit value for airborne Mn is 0.02 mg/m3 as per the guidelines by American Conference 
of Governmental Industrial Hygienists. However, subclinical health effects due to chronic 
exposure to Mn lower than this threshold are still unclear (Barceloux and Barceloux 1999).  One 
population that continues to be exposed to Mn are welders through Mn-containing welding fumes 
(Bowler et al. 2006) and the motor symptoms developed due to chronic exposure to Mn will remain 
even after cessation of overexposure to Mn (Perl and Olanow 2007). Hence it is essential to 
determine the risk associated with Mn toxicity in welders before the onset of clinical symptoms 
by establishing a diagnostic biomarker.  
Since Mn is a paramagnetic metal, one possible method to assess the Mn deposition in the brain is 
magnetic resonance imaging (MRI). Mn reduces the T1 relaxation time, increases the T1-weighted 
intensity and T1-relaxation rates of the MRI (Dorman et al. 2006; Newland et al. 1989). Increase 
in the T1-weighted MRI signal in the extra-pallidal basal ganglia (caudate and putamen) has been 
studied as a Mn neurotoxicity associated biomarker in the humans (Sen et al. 2011). Another 
method known as magnetic resonance spectroscopy (MRS) was used to determine the levels of 𝛾-
aminobutyric acid, the primary inhibitory neurotransmitter in the central nervous system, and 
found to be higher in the thalamus region of welders compared to controls (Ma et al. 2018). 
Manganism can also be differentiated based on the Unified Parkinson Disease Rating Scale, Motor 
Subsection 3 (UPDRS3). However, MRI and MRS are very expensive to be accessible and the 
UPDRS3 scale can only be applied when motor symptoms are present, hence not satisfied as 
effective early biomarkers of manganism.  
Recently, exosomes are becoming increasingly popular due to their involvement in intercellular 
communication. Exosomes are 40-120nm sized vesicles of endocytic origin that are formed by 
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intra luminal budding of multivesicular endosomes. Exosomes carry a cargo consisting of proteins, 
lipids and nucleic acids over a long distance between cells (Yanez-Mo et al. 2015). Biomarker 
value of an exosome is widely exploited in cancer biology to identify the nucleic acids associated 
with a particular type of cancer (Nedaeinia et al. 2017). Furthermore, exosomes carries cell-to-cell 
transmission of misfolded αSyn upon Mn exposure, indicating the role of Mn in αSyn protein 
misfolding (Harischandra et al. 2019). Interestingly, Mn exposure in non-human primates induced 
αSyn-positive aggregates in the brain (Verina et al. 2013), implicating protein aggregation in Mn-
induced Parkinsonism. Biomarker role of phosphorylated αSyn present in the cerebro spinal fluid 
(CSF), brain tissues and submandibular gland of PD patients is widely exploited using diagnostic 
techniques like immunohistochemistry, ELISA and western blotting (Beach et al. 2013; Majbour 
et al. 2016). Moreover, recently our group has established a highly sensitive and specific real-time 
quaking induced conversion (RT-QuIC) assay for the detection of misfolded proteins such as 
prions (Naveen Kondru et al. 2017; Manne et al. 2017; S. Jo Moore et al. 2017; M. Heather West 
Greenlee et al. 2016) and  αSyn (Harischandra et al. 2019; S. Manne et al. 2019). Hence, in the 
current study we adopted the RT-QuIC assay for enhanced detection of misfolded αSyn associated 
with the exosomal cargo of serum and plasma samples isolated from welders and healthy controls.  
Along with misfolded proteins, another important constituent of exosomes includes several small 
non-coding RNAs (ncRNA). Next-generation sequencing of exosomes will enables to identify 
several small RNAs including micro-RNA (miRNA), ribosomal RNA (rRNA), piwi-interacting 
RNA (piRNA), and transfer RNA (tRNA) (Li et al. 2014). Recent findings in various disease 
processes have found that exosomal RNAs play a crucial role in disease pathogenesis and have 
potential as biomarkers and therapeutic agents (Eacker et al. 2013; Lin and Gregory 2015; Lv et 
al. 2017). Mn also plays a significant role in regulating  the exosomal release of miRNA in cell 
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culture models of PD as evidenced by differential miRNA expression in exosomes isolated from 
the cell cultures treated with Mn. Despite of several advances in research, yet there is no validated 
biomarker available to detect  Mn neurotoxicity in occupationally exposed individuals like 
welders. Hence in the current study we performed RNA sequencing of exosomes derived from the 
serum of welders and healthy controls. Our results revealed distinct alterations in gene expression 
between welders and controls, indicating the selective packaging of the RNA cargo into exosomes 
varies with the physiological status of the individual. Overall, these results provide a key 
information about the biomarker role of exosomes for detecting the Mn associated neurotoxicity 
in welders using misfolded proteins and small RNAs. 
Materials and Methods 
Samples details 
All the human samples used in the manuscript were received on dry ice from the Penn State Milton 
S. Hershey Medical Center. Subjects were recruited initially from meetings of regional unions in 
Philadelphia and Harrisburg, Pennsylvania, and from the community around the Penn State Milton 
S. Hershey Medical Center. Welders were defined as subjects (45.8 ± 11.2 years old) exposed with 
within 90 days, and controls are those without a history of welding. All subjects were male, 
answered negatively for past Parkinson’s diagnosis or other neurological disorders, and were free 
of any obvious neurological or movement deficits using the Unified Parkinson’s Disease Rating 
Scale (UPDRS-III) with a threshold score of <15 (24). For detailed demographic information, 
including exposure metrics, blood metal levels and MRI measures [(R1 regional values and 
pallidal index (PI)] in welder and control cohorts, please refer to our previous publications (99, 
100). Written informed consent was obtained in accordance with guidelines approved by the Penn 
State Hershey Internal Review Board. Welders represented several different trades and industry 
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groups (e.g., boilermakers, pipefitters, railroad welders, and a variety of different manufacturing 
jobs). Controls were age-matched volunteers from the same regional community with various 
occupations. Whole blood samples were obtained by venipuncture. Serum and plasma samples 
were collected by centrifugations at appropriate speed. The serum and plasma samples were 
pipetted in 1 mL aliquots into 2.5 mL cryovials and stored at -80° C. Prior to sending samples to 
Iowa State, samples were blinded and shipped overnight. This serum and plasma were used to 
isolate exosomes as described above and was analyzed for misfolded αSyn content using RT-QuIC 
assay. These “blinded” samples were analyzed and reported back to Penn State for unblinding and 
further analysis. 
Purification of recombinant human αSyn protein by fast protein liquid chromatography 
(FPLC) 
Purification of recombinant human WT αSyn was performed as described in our recent 
publication.(Sireesha Manne et al. 2019) In brief, E. coli Rosetta DE2 cells were transformed with 
a human WT αSyn-expressing plasmid and plated on LB agar containing kanamycin (50 µg/mL). 
Single colonies were individually inoculated into tubes containing 5 mL LB media supplemented 
with kanamycin. The mini cultures were grown overnight at 225 rpm and 37 oC and expanded to 
1 L cultures. When the bacterial cultures reached an OD600 of 0.7, 1 mM IPTG was added to induce 
αSyn expression, and after 4.5 h, cultures were harvested by pelleting at 4200 x g for 20 min at 4 
oC. Later, bacterial pellets were lysed by adding 10 mL of 50 mM Tris and 500 mM NaCl at pH 
7.4 using an Omni tissue homogenizer and heat-precipitated at 85 oC for 15 min. The tubes were 
set on ice to cool down and all the subsequent steps were carried at 4 oC. The precipitates were 
removed by centrifugation at 15000 x g for 20 min at 4 oC and DNA was precipitated out by adding 
streptomycin (10 mg/ml) to the supernatants. The resulting solution was centrifuged at 23,000 x g 
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for 30 min, and the supernatant was 10-fold diluted and dialyzed using a 3-kDa MWCO snakeskin 
dialysis tubing in a 20 mM Tris HCl buffer at pH 8 overnight at 4 oC. Next day morning, the 
dialyzed supernatant was concentrated and filtered with a 0.2-µM filter before loading onto a 
Sephacryl 200 column (GE Healthcare Life Sciences) for the size-exclusion FPLC. The column 
was pre-equilibrated in 20 mM Tris-HCl buffer of pH 8 at 4 oC. Fractions having recombinant 
αSyn were determined based on Coomassie staining of the peak fractions. The Fractions positive 
for recombinant αSyn were combined, concentrated, and filtered using a 0.2-µm filter before 
loading onto a HiPrep Q FF 16/10 anion-exchange column. After the injection into FPLC, a wash 
step was performed using 50 mM NaCl for 5 column volumes followed with a linear gradient in 
10 column volumes up to 1 M NaCl in 20 mM Tris, pH 8, and αSyn protein was recovered between 
300 and 350 mM NaCl. The peak fractions were collected and analyzed through polyacrylamide 
gel electrophoresis followed by Coomassie staining to visualize the protein fractions. Fractions 
having protein were pooled and dialyzed in 20 mM Tris, pH 8, at 4 oC overnight. On the next day, 
the buffer was replaced with a new buffer for one hour and the protein was filtered using a 0.2-µm 
filter. Protein concentrations were estimated using a NanoDrop spectrophotometer with an 
extinction coefficient of 0.5960 M-1cm-1. The protein was lyophilized in aliquots with a final 
concentration of 1 mg/ml and stored at -80 oC until use.  
Polyacrylamide gel electrophoresis 
Protein fractions from size-exclusion or anion-exchange chromatography were mixed with an 
equal volume of 2X sample-loading buffer (2X Laemmli sample buffer, BIO-RAD) with 2-
mercaptoethanol, vortexed and boiled for 5 min. Proteins were separated by polyacrylamide gel 
electrophoresis using 4-20% gradient gels (BIO-RAD) followed by staining with Coomassie blue 




Determining the purity and activity of the recombinant αSyn protein                                                      
Purity of monomeric recombinant αSyn was confirmed by Coomassie stain. Additionally, we 
compared the thioflavin T (ThT) fluorescence intensity between monomeric recombinant αSyn 
versus aggregated αSyn (αSynagg) as described in our recent publication.(Sireesha Manne et al. 
2019)  Briefly, 95 µl of 25 µM ThT was added to a 384-well plate with 2.5-µl of monomeric 
recombinant αSyn or αSynagg and incubated at room temperature for 2 min. Fluorescence readings 
were taken at an excitation and emission wavelengths of 450 and 480 nm, respectively. We noticed 
an enhanced ThT fluorescence greater than 80-fold with αSynagg compared to monomeric 
recombinant αSyn. 
Exosome isolation from serum 
Serum samples were centrifuged at 1500 x g for 5 min to remove residual cells and debris. Later 
supernatant was transferred to a new 1.5 ml tube for exosome isolation. ExoQuick (Cat 
#EXOQ5A-1, System Biosciences, Palo Alto, CA) was added to the supernatant at 1:4 ratio 
(ExoQuick:Supernatant), mixed gently, and incubated for 30 min at 4°C.  After the incubation, 
centrifuged the samples at 1500 x g for 30 min to recover exosomes either to use for total RNA 
isolation or to use as a seed in the RT-QuIC assay.  
Exosome isolation from plasma 
Plasma samples were centrifuged at 1500 x g for 5 min to remove residual cells and debris. Later 
supernatant was transferred to a new 1.5 ml tube. Added 4 µl of thrombin (TMEXO-1) to 0.5 ml 
of plasma and incubated at room temperature for 5 minutes with mixing. Centrifuged the samples 
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at 10,000 rpm for 5 min to remove the fibrin pellet. Supernatants were treated as serum samples to 
isolate exosomes using an Exoquick reagent.   
RT-QuIC assay                                                                                                                                                                                                                    
The RT-QuIC assay was performed as described previously (Harischandra et al. 2019; N. Kondru 
et al. 2017; Manne et al. 2017; Sireesha Manne et al. 2019; S. J. Moore et al. 2017; M. H. West 
Greenlee et al. 2016) using a 96-well clear bottom plate (Nalgene Nunc International). The reaction 
mixture consists of final concentrations of reaction mixture consists of 300 mM NaCl, 10 µM 
EDTA, 20 µM Thioflavin-T with 0.2 mg/ml recombinant αSyn in each well. Prior to each reaction 
setup, the recombinant αSyn was filtered through a 100-kDa cutoff filter to retain monomer filtrate. 
Exosomes isolated from serum and plasma samples were resuspended in the  sterile PBS and made 
serial 10-fold dilutions with PBS. 5 µl of 10-2 (V/V) dilution of exosomes were added as a seed to 
95 µL of αSyn RT-QuIC reaction mixture per each well of a 96-well plate in the RT-QuIC assay. 
Next, the plates were sealed with a plate sealer (Nalgene Nunc International) and reactions were 
initiated in a CLARIOstar (BMG) plate reader with alternating 1-min shake and rest cycles (double 
orbital, 400 rpm) at 42 oC. ThT fluorescence readings were recorded at excitation and emission 
wavelengths of 450 and 480 nm, respectively, for every 30 min over a period of 60 h. After 
optimizing the RT-QuIC assay conditions, samples were assigned with numbers generated by 
random sequence generator and tested in a blinded manner in the RT-QuIC assay. Samples were 
run in quadruplicates and considered positive when at least two of the wells crossed the threshold 
fluorescence. Threshold fluorescence was calculated by taking the average fluorescence of the first 
10 cycles for all samples plus 10 standard deviations. Protein aggregation rates (PAR) for each 






Exosomal RNA isolation   
Exosomes isolated from the serum samples were processed and total RNA was isolated using the 
SeraMir Exosome RNA Purification Column kit (Cat #RA808A-1, System Biosciences, Palo Alto, 
CA) according to the manufacturer’s instructions. 1 µl of RNA elute was used for measuring small 
RNA concentration using Agilent Bioanalyzer Small RNA Assay in the Bioanalyzer 2100 Expert 
instrument (Agilent Technologies, Santa Clara, CA). 
Library generation and sequencing 
Small RNA libraries were constructed according to the manufacturer’s instructions with the 
CleanTag Small RNA Library Preparation Kit (TriLink, Cat# L-3206) and quantified the libraries 
with High Sensitivity DNA Reagents (Agilent Technologies, PO# G2933-85004) and High 
Sensitivity DNA Chips (Agilent Technologies, PO# 5067-4626).  Quantified libraries were pooled, 
and size selected from 140bp to 300bp region on a 8% TBE gel (Invitrogen by Life Technologies, 
Ref# EC6215).  Size selected libraries were quantified again with High Sensitivity DNA 1000 
Screen Tape (Agilent Technologies, PO # 5067-5584), High Sensitivity D1000 reagents (Agilent 
Technologies, PO# 5067-5585), and the TailorMix HT1 qPCR assay (SeqMatic, Cat# TM-505). 
Later NextSeq High Output single-end sequencing run at SR75 was done using a NextSeq 500/550 
High Output v2 kit (Cat #FC-404-2005, Illumina, San Diego, CA) according to the manufacturer's 




Exosomal αSyn aggregates as a potential biomarker of Mn exposure in humans 
We detected αSyn aggregates in exosomes isolated from serum and plasma samples collected from 
welders and controls using a highly sensitive and specific RT-QuIC assay. Recombinant human 
αSyn protein was used as a template to initiate the templated conversion reaction in the RT-QuIC 
assay. First, we tested serum exosome samples isolated from welders (n=29) and controls (n=16) 
in the RT-QuIC assay. By comparing the lag-phase of the average kinetic traces for misfolded 
seeded αSyn fibrillar formation and PAR values, we observed a significant difference between 
exosomes isolated from welders compared to control population exosomes (Fig. 1a and 1b). We 
noticed a similar trend in the ThT kinetic traces and PAR values of exosomes isolated from the 
plasma samples of welders (n=10) and controls (n=5) (Fig. 1c and 1d) indicating that exosomes 
isolated from welders have a higher seeding capacity and αSyn aggregates content compared to 
exosomes isolated from healthy controls. Collectively, identification and validation of novel serum 
and plasma exosome-based biomarkers using the RT-QuIC assay for evaluating risk to welders 
would enable the prompt institution of aggressive management measures to combat adverse effects 
of metal-induced Parkinsonism.  
Small RNA profiles of serum exosomes 
RNA sequencing of exosomes allows to analyze the identity and abundance of whole 
transcriptome of exosomes which consists of several non-coding small RNAs (ncRNA) including 
ribosomal RNA (rRNA), micro RNA (miRNA), transfer RNA (tRNA), pi-wi interacting RNA 
(piRNA), and long intergenic non-coding RNA (lincRNA).  We isolated exosomes from welders 
and control serum samples, purified the exosomal total RNA and built Illumina NGS libraries. 
These libraries were then sequenced and two rounds of quality checks on sequence data are 
performed to ensure the read quality before mapping the raw data to the genome. After quality 
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checks, raw sequencing data was mapped to the human genome to determine the sequencing read 
mapping rate, with trimmed, mapped and unmapped reads displayed as a percentage of reads and 
as total read counts (Fig. 2a). The trimmed reads are the set of reads filtered out during the data 
preprocessing step of the analysis. The remaining reads were used as input for the mapping step 
and are displayed in the chart as either mapped or unmapped reads. After read mapping, data 
analytics were undertaken to determine the expression analysis of small ncRNA and repeat element 
abundance level. Exosome Small RNA-seq Analysis Kit identifies and maps miRNAs, tRNAs, 
small rRNAs, repeat elements, antisense transcripts and a variety of small ncRNAs. Expression 
summary chart with abundance levels of all small ncRNAs of both welders and control samples is 
generated for easy understanding (Fig. 2b). Together, these results indicate that Mn exposure 
significantly alters small ncRNAs released via exosomes. 
Differential expression of small RNAs  
To identify the various small RNA changes associated with occupational exposure to welding 
fumes in welders, we examined the differential expression profiles of various small RNAs 
including miRNA, rRNA, lincRNA, piRNA, and tRNA, among serum exosomes of welders and 
controls were visualized by  expressing as  a heatmaps (Fig. 3a to 3e). Recently, several miRNAs 
regulating the synthesis of αSyn were identified in experimental models of PD (Majidinia et al. 
2016; Xie and Chen 2016), thus suggesting a role in the pathogenesis of neurodegenerative 
diseases. Many miRNAs and misfolded proteins (Syn, -amyloid and tau) have been identified 
as putative biomarkers of occupational and environmental exposures to polycyclic aromatic 
hydrocarbons, dioxin, metal-rich particulate matter, As, Pb and many others (Bollati et al. 2010; 
Eid and Zawia 2016; Gielen et al. 2016). Since miRNAs constitutes the most abundant among 
various small RNAs present in the exosomes, we identified some of the key upregulated (> 3 fold) 
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and downregulated (< 3 fold) miRNAs in welders (shown in red) compared to control samples 
(shown in blue) and plotted as a bar charts (Fig. 4a and 4b). Target genes and functional 
annotations associated with some key upregulated and downregulated miRNAs were predicted 
using an online database miRDB and summarized in Table. 1(upregulated miRNA) and 2 
(downregulated miRNA).  Together, these results will indicate the alterations of various small 
RNAs especially miRNAs expression in the exosomes due to exposure to welding fumes. 
Discussion  
Taken together, our results indicate the biomarker role of αSyn aggregates and various small 
ncRNAs associated with the exosomal cargo of human serum samples upon Mn exposure. Data 
from epidemiological and biochemical studies suggests that exposure to environmental toxins and 
pesticides can reproduce the neuropathological and neurochemical changes associated with the PD 
(Betarbet et al. 2000). Additionally, exposure to environmental toxicants like Mn induced the 
aggregation of αSyn in grey and white matters of frontal cortex of non-human primates (Verina et 
al. 2013) Moreover, chronic occupational exposure to high levels of Mn by welding is known to 
cause parkinsonian like disorder known as manganism, which is characterized by tremors, rigidity 
and psychosis (Racette et al. 2017). Hence, it is essential to know the molecular mechanisms 
underlying αSyn aggregation driven by environmental factors.  
More recently, studies have shown that αSyn isolated from the exosomes of cerebrospinal fluid 
from PD cases was able to initiate the seeded aggregation (Stuendl et al. 2016). Despite of all these 
evidences, spread of  αSyn through exosomes is still a matter of debate.   Hence, we evaluated the 
exosomes isolated from the serum and plasma of welders and control groups for αSyn aggregates 
using highly sensitive RT-QuIC assay. Interestingly, we noticed a significant difference between 
the welders and control groups exosomes for  αSyn aggregates levels indicating the potential 
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biomarker role for evaluating the Mn associated neurotoxicity in the exposed populations. 
Recently, several small ncRNAs were identified in exosomes through deep sequencing approaches 
on RNA isolated from the exosomes (Bellingham et al. 2012). Isolated RNA were enriched relative 
to their originating cells indicating the preferential packing of RNA into the exosomes (Valadi et 
al. 2007). Even how these RNAs are sorted into the exosomes is still debatable. Furthermore, 
several exosomal miRNAs plays an important role in disease progression. For example, they can 
facilitate the rapid silencing of mRNAs in breast cancer cells (Melo et al. 2014), stimulate 
angiogenesis and facilitate metastasis in cancers (Anastasiadou and Slack 2014), promote 
neurodegeneration by propagating infectious prion proteins (Fevrier et al. 2004).  
However, the effect of environmental neurotoxicants like Mn on exosomal RNAs composition of 
humans exposed to welding fumes is poorly understood. Hence, in this study we want to analyze 
the small ncRNAs changes associated with the serum exosomes of welder’s population through 
next generation sequencing. We observed differential expression of several small ncRNAs 
including miRNA, piRNA, tRNA, lincRNA, and rRNA through RNA sequencing analysis (Fig. 
3a-e). To further explore the mechanism of RNA packaging into exosomal cargo, we performed 
ingenuity pathway analysis (IPA) to explore the to disease pathways associated with welding (Fig. 
5). Some of the top disease pathways identified in the welders include organ injury abnormalities; 
reproductive system diseases; inflammatory disease and response; renal and urological disease; 
and cancer. Several other studies have shown that exposure to welding causes the increased risk 
of delayed time to conception and reduced semen quality and quantity in welders (Mortensen 1988; 
Rachootin and Olsen 1983) supporting the disease pathways identified through IPA analysis.  
To conclude, Mn exposure through welding fumes can exacerbate the metal neurotoxicity by 
increasing exosome release, which allows identification of the measurable exosome-based 
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biomarkers such as αSyn aggregates and ncRNAs (Fig. 6). 
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Figure 1: Determination of aggregated  αSyn seeding activity in exosomes using the RT-QuIC 
assay. (A) Average Thioflavin T (ThT) fluorescence in welders serum exosome samples (shown 
in red) compared to control  exosomes (green), showing more aggregated α-Syn in welders sera 
exosomes compared to controls.  Tested 29 welders and 16 control samples in quadruplicates. (B) 
Confirmation of PAR values in welder (n=29) and control (n=16) serum exosome samples. (C) 
Average Thioflavin T (ThT) fluorescence in welders plasma exosome samples (red) compared to 
control  exosomes (green), showing more aggregated α-Syn in welders plasma exosomes 
compared to controls.  Tested 10 welders and 5 control samples in quadruplicates. (B) 
Confirmation of PAR values in welder (n=10) and control (n=5) plasma exosome samples. Each 








Figure 2: Sequencing read mapping rate and exosomal small RNA expression summary. (A) The 
charts show the percentage and number of reads, respectively, for trimmed, mapped and unmapped 
reads for each of the seven samples. (B) Small RNAs, including tRNA, rRNA, miRNA, snoRNA 
and other ncRNAs, as well as antisense transcripts and repeat sequences are displayed in a pie 






Figure 3: Heat map visualization of serum exosomal small RNA expression of welders and control 
samples. (A) miRNA. (B) rRNA. (C) lincRNA. (D) piRNA. (E) tRNA. Scale at the bottom 
showing the lower to higher intensity levels.  
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Figure 4: Key miRNA associated with the exosomes. (A) Significantly upregulated miRNA (>3 
fold) in welders (red) compared to controls (blue). (B) Significantly downregulated miRNA (<3 














Figure 6: Schematic representation of biomarker role of exosomal RNAs and αSyn aggregates in 


















Description Role Reference 
hsa-miR-
6503-5p 
DNAJC6 DnaJ heat shock 
protein family 
(Hsp40) member C6 
 
Mutations in gene lead to 






VPS53 VPS53, GARP 
complex subunit 
Involved in retrograde 






STC1 Stanniocalcin 1 Promote cell apoptosis 
via NF-kB phospho-P65 
Ser536 in cervical cancer 
cells 




ICAM2 Intercellular adhesion 
molecule 2 
Involved in immune 
response and surveillance 
(Carrithers 
et al. 2000) 
hsa-miR-
4659b 
ZMYND8 zinc finger MYND-
type containing 8 
Involved in tumor 
angiogenesis 
(Kuroyanagi 
et al. 2014) 
hsa-miR-
3909 
RHBDL2 rhomboid like 2 Release soluble growth 
factors by proteolytic 
cleavage  






Table. 1 continued 
hsa-miR-
489 
NRIP1 nuclear receptor 
interacting protein 1 
Modulates the 
transcriptional activity of 
the estrogen receptor 
(Augereau 
et al. 2006) 
 





Description Role Reference 
hsa-miR-
4656 
PUM2 Pumilio RNA binding 
family member 2 
 
RNA binding protein. 
Functions as a 
translational repressor 













store operated Ca2+ entry. 
(Diez-




SIK3 SIK family kinase 3 Important for cell 
proliferation, metastasis 
and inflammation of 




















RAP2A RAP2A, member of RAS 
oncogene family 
Promotes the migration 
and invasion of cancer 
cells through 
upregulating p-Akt 




PSMB2 Proteasome subunit beta 
2  
Multicatalytic proteinase 
complex that cleaves 
peptides in 
ATP/ubiquitin 
dependent process.  




GATAD2B GATA zinc finger 
domain containing 2B 
Encodes zinc finger 
protein transcriptional 
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Abstract 
Adult-onset neurodegenerative disorders, like Parkinson’s disease (PD) and dementia with Lewy 
bodies (DLB), that share the accumulation of aggregated α-synuclein (αSynagg) as their hallmark 
molecular pathology are collectively known as α-synucleinopathies. Diagnosing α-
synucleinopathies requires the post-mortem detection of αSynagg in various brain regions. Recent 
efforts to measure αSynagg in living patients include quantifying αSynagg in different biofluids as a 
biomarker for PD. We adopted the real-time quaking-induced conversion (RT-QuIC) assay to 
detect very low levels of αSynagg. We first optimized RT-QuIC for sensitivity, specificity, and 
reproducibility by using monomeric recombinant human wild-type αSyn as a substrate and αSynagg 
as the seed. Next, we exposed mouse microglia to αSyn pre-formed fibrils (αSynPFF) for 24 h. RT-
QuIC assay revealed that the αSynPFF is taken up rapidly by mouse microglia, within 30 min, and 
cleared within 24 h. We then evaluated the αSyn RT-QuIC assay for detecting αSynagg in human 
PD, DLB, and Alzheimer’s disease (AD) post-mortem brain homogenates (BH) along with PD 
and progressive supranuclear palsy (PSP) cerebrospinal fluid (CSF) samples and then determined 
protein aggregation rate (PAR) for αSynagg. The PD and DLB BH samples not only showed 
significantly higher αSynagg PAR compared to age-matched healthy controls and AD, but RT-
QuIC was also highly reproducible with 94% sensitivity and 100% specificity. Similarly, PD CSF 
samples demonstrated significantly higher αSynagg PAR compared to age-matched healthy 
controls, with 100% sensitivity and specificity. Overall, the RT-QuIC assay accurately detects 
αSynagg seeding activity, offering a potential tool for antemortem diagnosis of α-synucleinopathies 
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Introduction 
Brain pathologies collectively known as α-synucleinopathies are characterized by the abnormal 
accumulation of α-synuclein aggregates (αSynagg). Some of these disorders include Parkinson’s 
disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Lewy 
bodies are a pathological hallmark in PD and DLB patients whose neurons are rich in deposits of 
αSynagg (Spillantini et al. 1998). In contrast, MSA patients have αSynagg deposits in 
oligodendrocytes as glial cytoplasmic inclusions (Tu et al. 1998). Although it is rare, the 
accumulation of Lewy bodies also occurs in progressive supranuclear palsy (PSP) cases, which is 
normally characterized by the accumulation of neurofibrillary tangles (NFT’s) composed of 
phosphorylated tau protein (Mori et al. 2002). The highly charged, intrinsically disordered acidic 
protein αSyn is encoded by the SNCA gene and plays a key role in presynaptic vesicle trafficking 
(Allen Reish and Standaert 2015; Spillantini et al. 1995). This protein has the propensity to 
oligomerize and further trigger the host’s innate and adaptive immune responses that may 
contribute to PD pathology (Stone et al. 2009). Conversely, neuroinflammation has been 
implicated in promoting the prion-like oligomerization of αSyn (Lema Tomé et al. 2013). 
Epidemiological evidence has linked the use of non-aspirin anti-inflammatory drugs to a 15% 
reduction in PD incidence, suggesting that drugs that lower neuroinflammation might be an 
effective treatment against PD. Furthermore, targeting microglia-mediated neuroinflammation 
remains an attractive target for treating PD progression (Gupta et al. 2018; Williams et al. 2018).  
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A definitive diagnosis of α-synucleinopathy can be made only by identification of αSynagg in post-
mortem brain tissues (Marti et al. 2003). Indeed, the clinical presentation of these movement 
disorders overlaps, thus making a conclusive diagnosis difficult and dependent primarily on a 
thorough history and an assessment of motor deficits during a comprehensive physical exam. 
Despite an urgent need, currently no biomarker is available to diagnose or monitor clinical 
outcomes in Parkinsonian disorders. Thus, the development of biomarkers for these disorders 
would be a major advance in the field as it would improve the accuracy of clinical diagnoses, 
treatment plans, and patient/family counseling; aid in monitoring the efficacy of therapeutic agents 
on disease processes; and facilitate the accurate recruitment of patients for clinical trials and 
research. Although biomarkers for the differential diagnosis of α-synucleinopathies currently are 
not available, several groups are actively pursuing them using a variety of approaches including 
the assessment of biofluids, motor performance tests, and imaging technologies. Developing a 
diagnostic test for these disorders is very challenging due to individual variation in the progression 
and severity of the diseases. Several teams have focused on the biomarker potential of αSyn and 
its various forms (total, oligomeric, and phosphorylated) in biofluids, employing distinct 
quantitative assays like ELISA, time-resolved Forster’s resonance energy transfer (TR-FRET), and 
immunoassays (Bidinosti et al. 2012; Compta et al. 2015; Hall et al. 2015; Wang et al. 2012).  
Levels of αSyn in the CSF differ widely between patient cohorts (Ohrfelt et al. 2009; Tokuda et 
al. 2010) and the labor-intensive preparation requirements of immunoassay techniques have 
limited the high-throughput, clinical application of these diagnostic tests.  
Since αSynagg deposits appear as an early pathological event that occurs prior to the development 
of clinical signs (Braak et al. 2006), we explored its diagnostic utility as a biomarker. Prior to this 
work, we had demonstrated the viability of applying the real-time quaking-induced conversion 
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(RT-QuIC) assay for the antemortem detection of chronic wasting disease-causing scrapie prions 
in rectal biopsies (Manne et al. 2017). Based on the observation that αSynagg shares prion-like 
properties in the templated conversion of monomeric αSyn, we similarly developed and optimized 
the RT-QuIC assay for the ultrasensitive detection of αSynagg in biological samples. In α-
synucleinopathies, evidence suggests that activated microglia are the most efficient scavengers of 
extracellular αSynagg (Lee et al. 2008). We thus compared the uptake and clearance of αSyn pre-
formed fibrils (αSynPFF) by microglia and detected the seeding activity from activated microglia 
using the αSyn RT-QuIC assay. After determining microglial seeding activity, we used the αSyn 
RT-QuIC assay for diagnosing α-synucleinopathies. Meanwhile, three other groups independently 
developed a similar αSyn RT-QuIC assay for diagnosing α-synucleinopathies with comparably 
high sensitivities and specificities (Fairfoul et al. 2016a; Groveman et al. 2018b; Sano et al. 2018). 
In the present study, we tested a total of 31 CSF samples and 45 brain homogenates (BHs) from 
two different patient cohorts using our αSyn RT-QuIC assay. Collectively, our results demonstrate 
that misfolded αSyn seeding activity can be detected in activated microglia, CSF and BHs using 
the αSyn RT-QuIC assay.  
Results 
Expression and purification of monomeric human wild-type αSyn from E. coli.   
Since the purity of the monomeric αSyn substrate is a critical determinant of the RT-QuIC assay, 
we generated a highly suitable recombinant human wild-type (WT) αSyn using a bacterial 
expression system followed by fast-protein liquid chromatography for purification.  As described 
in the Methods, E. coli expressing αSyn were pelleted and lysed. Overnight-dialyzed lysates were 
fractionated using size-exclusion (Fig. 1a) and anion-exchange chromatography (Fig. 1b). 
Coomassie staining of the fractions from size-exclusion (Fig. 1c) and subsequent anion-exchange 
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(Fig. 1d) chromatography revealed the achievement of a pure monomer of recombinant WT αSyn 
protein. Only recombinant monomers of αSyn protein that passed our quality control criteria were 
used for the preparation of αSynagg and αSynPFF as well as a substrate in the αSyn RT-QuIC assay.  
Generation and characterization of αSynagg and αSynPFF from recombinant human αSyn 
monomers 
Like infectious prion proteins, endogenous αSynagg is required for conversion of monomeric αSyn 
into more pathogenic αSynagg. We generated and characterized αSynagg and αSynPFF from 
monomeric αSyn according to the protocol set forth by the Michael J. Fox Foundation (Polinski et 
al. 2018). We generated αSynagg from pure monomeric human αSyn by continuous shaking for 
seven days over a thermal cycler (described in Methods). The αSynagg was sonicated using a probe 
sonicator to further generate αSynPFF. Both the αSynagg and αSynPFF were visualized for 
morphology and size by transmission electron microscopy (TEM) performed before and after 
sonication. TEM pictures revealed significantly less αSynagg after sonication due to the presence 
of more αSynPFF (Fig. 2a).  Next, we confirmed the presence of αSynagg using a sedimentation 
assay after subjecting the αSynagg to ultracentrifugation. The supernatant and sediment fractions 
of αSynagg were separated using polyacrylamide gel electrophoresis. The successful formation of 
protein aggregates was indicated by the presence of substantially higher amounts of protein in the 
pellet fraction than in the supernatant (Fig. 2b).  To further confirm this result, we tested the 
seeding activity of our newly generated αSynagg using the αSyn RT-QuIC assay. Various 
concentrations of αSynagg were tested for their ability to convert monomeric recombinant αSyn 
into the aggregated form. We detected a dose-dependent amplification in fluorescence kinetics 
with various doses of αSynagg (Fig. 2c) and an increase in protein aggregation rates (PAR) (Fig. 
2d). The enhanced thioflavin T (ThT) fluorescence of the αSynagg we generated exceeded that of 
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monomeric αSyn by more than 80-fold (Fig. 2e), and a well-area scan image showed the deposition 
of intense amyloids in the αSynagg (red color) compared to the monomeric αSyn (grey color) (Fig. 
2f). 
Determination of misfolded αSyn seeding activity in glial cells 
Studies have shown that αSynagg is taken up and cleared by microglia (Lee et al. 2008), inducing 
a neuroimmune response, but the clearance rate of αSynagg is not well characterized. To determine 
the   αSynagg uptake and clearance rate in microglia, we exposed a mouse microglial cell line to 1 
µM αSynPFF, which was generated by sonicating αSynagg as described in Methods.  After αSynPFF 
exposure, cells were harvested in ice-cold PBS at the post-treatment endpoints 0, 0.5, 2, 6, 12 and 
24 h. From each lysate, 5 pg/well (Fig. 3a & 3c) and 50 pg/well (Fig. 3b & 3d) were loaded into a 
96-well plate that used monomeric αSyn as a substrate in the RT-QuIC assay. Steady-state αSyn 
protein seeding activity (Fig. 3a & 3b) and aggregation (Fig. 3c & 3d), reported as protein 
aggregation rate (PAR), were detected starting at 0.5 h and maintained at steady-state up to 12 h 
post-αSynPFF treatment, and then both declined gradually over time before returning to basal levels 
at 24 h, suggesting that αSynPFF is taken up rapidly by microglia, within 30 min, and reduced within 
24 h. Collectively, our data demonstrate the degradation efficiency rate at which microglial cells 
scavenge αSynPFF present in the extracellular milieu. 
Determination of misfolded αSyn seeding activity from CSF samples 
We next performed a blinded analysis using the αSyn RT-QuIC assay on a subset (Table 1) of CSF 
samples obtained from PD (n=15) and control (n=11) subjects. All 15 PD CSF samples tested 
positive within 20-40 h, as compared with control cases, further highlighting the diagnostic 
sensitivity of the proposed assay (Fig. 4a). The calculated αSyn PAR of CSF differed significantly 
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between controls and PD samples (Fig. 4b). A small set of non-synucleinopathy (NS) cases 
consisting of PSP (n=5) and control (n=5) subjects were also tested in the αSyn RT-QuIC assay. 
Two of the five PSP cases were amplified in the αSyn RT-QuIC assay, indicating the presence of 
Lewy body pathology in PSP cases (Fig. 4c). However, the PAR values of amplified PSP cases 
did not significantly differ from control cases (Fig. 4d). None of the controls met criteria to be 
considered positive RT-QuIC responses, further supporting the specificity of the assay. Our results 
indicate that the CSF αSyn RT-QuIC assay can be applied to a larger PD cohort to further validate 
the diagnostic accuracy of the assay. 
Determination of misfolded αSyn seeding activity from BHs 
To further validate the αSyn RT-QuIC assay, we analyzed BH samples from two independent brain 
banks: the UC Davis Alzheimer's Disease Center provided DLB (n=5), Alzheimer’s disease (AD; 
n=10), and control (n=8) samples, while the University of Miami's Brain Endowment Bank 
provided PD and control samples (n=11 each) (Table 2). Among these, PD and DLB represent α-
synucleinopathies, whereas AD and controls represent NS samples. NS cases did not show ThT 
fluorescence above the threshold level over the entire 70-h RT-QuIC reaction period. To determine 
the optimal working concentration of BH, various BH dilutions (1:1000 to 1:1,000,000) from a 
small set of samples (3 PD and 2 controls) were tested in the αSyn RT-QuIC assay (Fig. 5). Of all 
the dilutions tested within the specified range, only the 1:10,000 dilution amplified all the 
biological replicates at a similarly early time (around 10 h) (Fig. 5b vs 5a, c, d); therefore, we used 
1:10,000 dilution for further testing of a larger set of samples. Next, all BHs of 10-4 dilutions were 
tested for misfolded αSyn seeding activity in the αSyn RT-QuIC assay (Fig. 6). All DLB (5/5) and 
most of the PD (10/11) samples were amplified using the RT-QuIC assay for a period of 20 or 30 
h, respectively, whereas the control BHs failed to demonstrate any amplification (Fig. 6a & 6c), 
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indicating high sensitivity and specificity of the αSyn RT-QuIC assay. Similarly, the PAR for 
controls was significantly lower than that for the DLB and PD groups (Fig. 6b & 6d). Interestingly, 
two AD samples showed enhanced seeding activity and PAR (Fig. 6a-b), suggesting the presence 
of some αSyn pathology in these AD BHs, which is consistent with previous findings (Hamilton 
2000; Waxman and Giasson 2011).  
Immunoreactivity using a αSyn filament conformation-specific antibody 
To further confirm the presence of misfolded αSyn in human BHs, we performed a dot blot analysis 
using an αSyn filament conformation-specific antibody in BHs of PD, DLB, AD and controls 
obtained from the two brain banks. Immunoblotting revealed the presence of misfolded αSyn in 
DLB (Fig. 7a, top panel; 7b) and PD (Fig. 7d, top panel; 7e) BHs compared to control and AD 
cases.  Interestingly, the same two AD BH samples that amplified in the αSyn RT-QuIC assay also 
showed positive results using the αSyn filament-specific antibody, indicating the possible presence 
of αSyn pathology in these two AD cases (Hamilton 2000) (Fig. 7a, top panel). One control 
exhibited higher staining intensity for the αSyn filament form (Fig. 7a). This may be due to a non-
PD-related increase in the staining intensity. This control subject had a metastatic tumor, and the 
role of its underlying pathology on αSyn aggregation is not known. Furthermore, our study used 
only one brain region (SN) obtained from the autopsy brains. Considering the history of this control 
subject, and its lack of apparent seeding activity in RT-QuIC reactions, we removed this control 
from statistical analysis in Fig. 7b using the robust regression and outlier removal method (ROUT 
in Prism 7.0, GraphPad). The immunoblots also were stained for total αSyn to reveal the presence 
of similar αSyn levels among these groups (Fig. 7a & 7d, bottom panels; 7c & 7f). Collectively, 
these results suggest that significantly higher levels of misfolded αSyn can be observed among α-
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synucleinopathy patients as compared to NS cases, but total αSyn levels remained unchanged 
across all groups. 
Discussion 
The accumulation of αSynagg is the main pathological event in neurodegenerative α-
synucleinopathies like PD, DLB, and MSA. Early and accurate diagnosis of these disorders has 
been hampered by the lack of a well-characterized, sensitive diagnostic assay, thereby resulting in 
ineffective treatment strategies and delayed counseling of patients and their families. Diagnosis of 
PD is made after  ~50-70% of dopaminergic neurons are lost and is based on patient history and 
presence of the cardinal motor symptoms, such as bradykinesia, rigidity, and tremor (Hughes et 
al. 1992). A recent study indicates that the accuracy of clinical diagnoses of PD is only 60% (Beach 
and Adler 2018) due to PD symptoms overlapping with other Parkinsonian syndromes such as PSP 
and MSA. A definitive diagnosis has been possible only by post-mortem evaluation using 
immunohistochemistry (Braak and Braak 2000; Holdorff 2006). Currently, no in vivo biomarkers 
are approved to differentiate between these clinically similar syndromes and to capture their 
distinctive pathological patterns and molecular characteristics. Detection of αSynagg as a diagnostic 
biomarker offers a promising approach.  However, recent reports of using the αSyn RT-QuIC assay 
to detect αSynagg in CSF and BH samples of α-synucleinopathy (Fairfoul et al. 2016a; Groveman 
et al. 2018b; Sano et al. 2018) stopped short of assessing reproducibility and sensitivity of the 
assay. Herein, we assessed the reproducibility, sensitivity, and specificity of the αSyn RT-QuIC 
assay using CSF and BH samples from two different brain banks. To achieve an accurate diagnosis, 
having pure recombinant αSyn is a key determinant in the RT-QuIC assay, and hence we generated 
a recombinant human WT αSyn and optimized the RT-QuIC assay conditions by generating 
αSynagg from recombinant αSyn. Other causes of neurodegeneration in α-synucleinopathy include 
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neuronal damage caused by activated microglia. Anti-inflammatory therapies that target activated 
microglia have been shown to slow-down disease progression (Block et al. 2007).  We adopted 
the αSyn RT-QuIC assay to detect αSynPFF internalized in microglia by analyzing the seeding 
activity within microglia incubated with αSynPFF for varying time periods. Our results 
demonstrated that αSynPFF stays at steady state for 12 h before degrading within 24 h, suggesting 
the anti-inflammatory therapy should be administered at early stages of protein aggregation.  
Next, we exploited the ability of the αSyn RT-QuIC assay to measure αSynagg levels in human 
CSF samples. We achieved 100% sensitivity and specificity with a blinded analysis of a subset of 
CSF samples. Among the PSP cases tested in the αSyn RT-QuIC assay, two cases showed 
enhanced ThT fluorescence, indicating the presence of Lewy body pathology consistent with 
previous findings (Mori et al. 2002; Uchikado et al. 2006). Later, we tested a set of BH samples 
received from two independent brain banks for determining misfolded αSyn seeding activity. 
Based on results using BHs, we were able to differentiate α-synucleinopathy (DLB and PD 
patients) from controls with 94% sensitivity and 100% specificity. Along with α-synucleinopathy 
samples, two AD samples also amplified in the RT-QuIC assay and this might be due to the 
presence of αSyn pathology (Hamilton 2000). Collectively, these results demonstrate the power of 
the αSyn RT-QuIC assay in distinguishing α-synucleinopathy cases from controls. Furthermore, 
dot blot quantification of αSynagg levels in BHs using an αSyn filament conformation-specific 
antibody also revealed significant differences among α-synucleinopathy cases and controls. 
Furthermore, dot blot intensities for αSyn filament conformation-specific antibody in BH samples 
from DLB and PD patients were positively correlated with their respective PARs from the αSyn 
RT-QuIC assay (supplement Fig. 1).  
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Overall, our results highlight the high level of sensitivity and reproducibility of the αSyn RT-QuIC 
assay using a recombinant human αSyn as a substrate as well as the detection of αSynagg 
sequestered within microglia, CSF and BHs. Clearly, further validation using larger sample sizes 
is needed to demonstrate the utility of the αSyn RT-QuIC assay in discriminating among α-
synucleinopathies by further establishing the efficacy of αSynagg as a biomarker for those 
neurodegenerative disorders having the propensity to accumulate aggregate-prone proteins. In 
terms of clinical relevance to disease progression in Parkinsonism, monitoring disease progression 
and/or response to therapy continues to be a valuable objective of this technique. Using larger 
cohorts consisting of samples at various stages of disease progression, the kinetics associated with 
the αSyn RT-QuIC assay could be validated for indirectly assessing the concentration of 
pathological αSyn aggregates in samples.  We propose that integrating αSyn and tau RT-QuIC 
assays with multi-model brain imaging modalities would have important clinical value in 
monitoring disease progression, differential diagnosis and clinical monitoring of disease-
modifying pharmacotherapies. 
Materials and Methods 
Lumbar puncture and cerebrospinal fluid (CSF) sample storage  
CSF samples were collected as part of the NINDS Parkinson’s Disease Biomarker Program 
(PDBP) according to guidelines (Rosenthal et al. 2016) for the lumbar puncture. The protocol was 
reviewed and approved by the Penn State Hershey Internal Review Board and informed written 
consent was obtained from all subjects. After CSF collection, samples were centrifuged for 5 min 
at 4 oC and 1300 x g to remove cellular debris. The supernatant was aliquoted into 1-mL samples 
and stored long-term in cryovials at -80 oC. Individual 1-mL samples from control and PD subjects 
(n=5 each) were thawed, and then 300 µL were transferred to a cryovial with a generic label to 
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blind investigators at Iowa State. These samples then were frozen and shipped overnight on dry-
ice to Iowa State University. Samples were stored at -80 oC upon arrival and prior to analysis 
(Table 2).  
Autopsy brain samples 
Brain tissues were provided by the Brain Endowment Bank from the University of Miami and 
UC Davis Alzheimer’s Disease Center. All tissues were frozen at -80 oC upon arrival and stored 
at -80 oC prior to analysis. From the University of Miami, substantia nigra tissue from 11 PD and 
11 control patients were obtained. The UC Davis Alzheimer’s Disease Center provided slices of 
basal ganglia from 5 DLB, 10 AD, and 8 control patients. All tissues had been examined 
histologically for accurate diagnoses using accepted criteria (Montine 2012) prior to testing in 
the RT-QuIC assay. 
Preparation of BHs 
From the frozen brain sections, 10% W/V BHs were prepared in sterile PBS using a Bullet Blender 
(Next Advance) with 0.5-mm Zirconium oxide beads for 2 min at the maximum speed. The 10% 
homogenates were stored at -80 oC until use. Various dilutions of BHs, ranging from 10-2 to 10-6, 
were made using PBS, and the 10-4 dilution was used for testing all the samples in the RT-QuIC 
assay.  
Recombinant αSyn protein purification 
A plasmid expressing human WT αSyn was a generous gift from Dr. Julien Roche (Iowa State 
University). Recombinant human WT αSyn was purified as described previously (Maltsev et al. 
2012; Volpicelli-Daley et al. 2014) with a few modifications. In brief, a loop-full inoculum of 
human WT αSyn-expressing Rosetta cells in glycerol stock was added to 5 mL of LB media 
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supplemented with 50 µg/mL kanamycin and grown overnight at 225 rpm and 37 oC. Next, mini-
cultures were grown in 1 L of kanamycin-LB media, and when the OD600 reached 0.7, 1 mM IPTG 
was added into the bacteria. Cells were harvested 4.5 h later by pelleting at 4200 x g for 20 min at 
4 oC. Bacterial pellets were lysed by dissolving them in 10 mL of 50 mM Tris and 500 mM NaCl 
at pH 7.4 using an Omni tissue homogenizer. Following lysis, the cell suspension was sonicated 
for 2 min using a high setting on a probe sonicator that was paused every 15 sec. Samples then 
were heat-precipitated at 85 oC for 15 min. Later, the precipitates were removed by centrifugation 
at 15,000 x g for 10 min at 4 oC and DNA was precipitated by adding streptomycin (10 mg/mL) 
to the supernatants. The solution then was centrifuged at 23,000 x g for 30 min, and the supernatant 
was 10-fold diluted and dialyzed using a 3-kDa MWCO snakeskin dialysis tubing in a 20 mM Tris 
HCl buffer at pH 8 overnight at 4 oC. The next morning, the dialyzed supernatant was concentrated 
and filtered with a 0.2-µM filter before loading onto a Sephacryl 200 column (GE Healthcare Life 
Sciences) for size-exclusion chromatography using a 20 mM Tris-HCl buffer of pH 8 at 4 oC. 
Fractions having recombinant αSyn were pooled, concentrated and filtered using a 3-kD cut-off 
filter and analyzed with gel electrophoresis. Later, Coomassie staining was performed and 
fractions having recombinant αSyn were combined, concentrated, and filtered using a 0.2-µm filter 
before loading onto a HiPrep Q FF 16/10 anion-exchange column. A linear gradient was run up to 
1 M NaCl in 20 mM Tris, pH 8, and αSyn protein was recovered between 300 and 350 mM NaCl. 
Fractions were collected and analyzed through polyacrylamide gel electrophoresis followed by 
Coomassie staining to visualize the protein fractions. Fractions having protein were pooled and 
dialyzed in 20 mM Tris, pH 8, at 4 oC overnight. On the next day, the buffer was replaced with a 
new buffer for one hour and the protein was filtered using a 0.2-µm filter. Protein concentrations 
were estimated using a NanoDrop spectrophotometer with an extinction coefficient of 0.5960 M-
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1cm-1. The protein was lyophilized in aliquots with a final concentration of 1 mg/mL and stored at 
-80 oC until use.   
Polyacrylamide gel electrophoresis 
Protein fractions from size-exclusion or anion-exchange chromatography were mixed with an 
equal volume of 2X sample-loading buffer and 2-mercaptoethanol (2X Laemmli sample buffer, 
BIO-RAD), and boiled for 5 min. Proteins were separated by polyacrylamide gel electrophoresis 
using 4-20% gradient gels (BIO-RAD) followed by staining and destaining with Coomassie Blue.  
Generation of αSynagg and αSynPFF from recombinant WT αSyn   
We generated αSynagg and αSynPFF from the recombinant αSyn according to published methods 
(Polinski et al. 2018).  In brief, 100 μL solution of 5 mg/mL recombinant WT αSyn in PBS with 
100 mM NaCl was subjected to continuous 1000 rpm shaking at 37 °C for 7 days in a 1.5-mL tube. 
Later, the products were verified for the presence of ThT-positive αSyn aggregates. Western blot 
analysis of ultra-centrifuged aggregates revealed that pellets have more αSynagg than supernatant 
fractions. To generate αSynPFF, the αSynagg was probe-sonicated at power level 2 for a total of 60 
pulses, pausing every 10-12 pulses. 
Sedimentation assay  
The αSynagg was diluted 10-fold using sterile PBS. Diluted αSynagg later was ultra-centrifuged at 
100,000 x g for 30 min at 25 oC. Supernatants and pellets were diluted with 5X Laemmli buffer 
and boiled for 5 min. Equal volumes of supernatants and pellets then were separated using 4-20% 






A 1-mM stock of ThT was diluted in PBS to a final concentration of 25 µM. This was used to add 
95 µL of ThT to each well of a 384-well plate. A 2.5-µL sample of αSynagg, monomeric 
recombinant αSyn or PBS alone was added to the 95 µL of ThT in the wells and incubated at RT 
for 2 min. Fluorescence readings were then taken on a plate reader at excitation and emission 
wavelengths of 450 and 480 nm, respectively.  
Scanning transmission electron microscopy (STEM) 
For STEM characterization, αSynagg and αSynPFF were resuspended in sterile PBS. Next, 20 µL of 
resuspended sample was mixed with 2% uranyl acetate and incubated for 5 min. Then, 5 µL of 
sample was applied to carbon-coated copper grids and images were taken with a JEOL 2100 200-
kV STEM operated at 80 kV. The analysis was done using a Thermo Fisher Noran System 6 
elemental analysis system.   
Cell culture and treatments 
A mouse microglial cell line was a gift from Douglas T Golenbock (U Mass) and cultured as 
described previously (Halle et al. 2008). Cells were maintained in DMEM F12 media 
supplemented with 9% FBS, penicillin/streptomycin, glutamine, and sodium pyruvate. Microglia 
were treated with 1 µM of αSyn PFFs prepared in serum-free media. After treatments, cells were 
collected at 0, 0.5, 2, 6, 12 and 24 h using ice-cold PBS. After estimating the protein 
concentrations, 5 and 50 pg of microglial lysate was used as a seed in the RT-QuIC assay.   
RT-QuIC method 
The αSyn RT-QuIC assay was done as published previously (Moore et al. 2017b; West Greenlee 
et al. 2016) using a 96-well clear bottom plate (Nalgene Nunc International). Briefly, samples were 
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loaded into each well of a 96-well plate preloaded with 6 silica beads 0.8 nm in diameter (OPS 
Diagnostics). For all the αSyn RT-QuIC assays, the reaction mixture consists of 40 mM phosphate 
buffer (pH 8.0), 170 mM NaCl, 10 µM ThT, and 0.1 mg/mL of recombinant αSyn. But for testing 
microglia and CSF samples, along with the above components, we also added final concentrations 
of 0.0015% sodium dodecyl sulfate (SDS) to the reaction mixture. For microglia samples, we 
loaded 5 µL of microglial lysate along with 95 µL of the reaction mixture in each well of a 96-
well plate. For CSF samples, we loaded 15 µL of CSF sample along with 85 µL of the reaction 
mixture in each well of a 96-well plate. For BH samples, we loaded 2 µL of diluted BH along with 
98 µL of the reaction mixture in each well of a 96-well plate. After loading the samples, plates 
were sealed with a plate sealer (Nalgene Nunc International) and ThT fluorescence readings were 
taken at excitation and emission wavelengths of 450 and 480 nm, respectively, every 30 min using 
a CLARIOstar (BMG) plate reader with alternating 1-min shake and rest cycles (double orbital, 
400 rpm) at 42 oC. Samples were run in quadruplicates and considered positive when at least two 
of the wells crossed the threshold fluorescence. Threshold fluorescence was calculated by taking 
the average fluorescence of the first 10 cycles for all samples plus 10 standard deviations. PAR 
was calculated by taking the inverse of the time required to cross the threshold fluorescence.  
Immunostaining 
Immunoreactivity of αSyn filaments from BHs of α-synucleinopathy and NS cases was determined 
by dot blot using a Bio-Dot Microfiltration System per manufacturer’s protocol as described 
previously (Kondru et al. 2017). In brief, after determining the protein concentrations of BHs using 
the Bradford assay, 1 μg of homogenate was mixed with 200 μL of Tris-buffered saline (1X TBS) 
with 0.1% Tween-20 and allowed to adsorb onto a nitrocellulose membrane for 1 h. The membrane 
was blocked with 1X LI-COR blocking buffer (LBB) for 30 min after washing twice with 200 μL 
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of 1X TBS using a gentle vacuum. The membrane then was incubated with a rabbit monoclonal 
(MJFR-14-6-4-2) αSyn filament conformation-specific antibody (dilution 1:2,000) and a mouse 
monoclonal (BD Biosciences, #610787) total αSyn antibody for 1 h at RT, and triple-washed with 
1X TBS. Membranes then were incubated with their respective secondary antibody made in LBB 
(1:10,000) for 30 min followed by 3 washes with 1X TBS. Immunoreactive proteins were detected 
using the Odyssey IR Imaging system along with the densitometric quantification of dots. 
Statistical analysis 
GraphPad 7.0 was used for statistical analysis with p≤0.05 considered statistically significant. Raw 
data were analyzed using Student’s t-test for comparing two groups, one-way ANOVA for 
analyzing more than two groups, and then Tukey’s post-test was performed to compare different 
groups. Asterisks were assigned as follows: *p ≤ 0.05, **p < 0.01, and ***p < 0.001. The number 
of biological replicates is expressed as “n” unless otherwise mentioned. 
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Fig. 1 Chromatogram showing the purification of recombinant human wild type (WT) αSyn and 
Coomassie staining of collected fractions. Here we purified the full length of recombinant human 
WT αSyn.  (a) Absorbance spectra for purification of WT rαSyn using a Sephacryl 200 column. 
(b) Absorbance spectra of the HiPrep Q FF 16/10 anion-exchange column. Dashed box denotes 
the peak fraction of the eluted protein. Coomassie Blue staining of total protein fractions collected 







Fig. 2 Validation of generated αSynagg and αSynPFF prior to use. (a) Scanning transmission electron 
microscopy (STEM) images of αSynagg before (scale bar = 100 nm) and after (scale bar = 500 nm) 
sonication, which converted long αSynagg into short αSynPFF while retaining beta-sheet 
conformation. (b) Sedimentation assay of ultra-centrifuged αSynagg showing more αSynagg in the 
pellet fraction than in the supernatant (Sup). (c) Dose-dependent seeding activity of αSynagg at 
various concentrations using the αSyn RT-QuIC assay. (d) PAR of αSynagg tested in the αSyn RT-
QuIC assay increased from lower to higher αSynagg concentrations. (e) Thioflavin T (ThT) assay 
confirmed the presence of αSynagg with higher ThT fluorescence for αSynagg than for recombinant 
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αSyn. (f) Well-scan image of αSynagg (red color) and recombinant αSyn (grey color) showing 



















Fig. 3 Detection of misfolded αSyn seeding activity in microglia. (a, b) ThT kinetics of microglia 
tested in the αSyn RT-QuIC assay after being incubated with αSynPFF for various time intervals, 
showing the clearance of αSynPFF by activated microglia within 24 h. (c, d) Comparison of PARs 
among various time intervals of αSynPFF-incubated microglia. Each trace and symbol represents 
the average of 4 replicates. We used 5 pg/well (a, c) and 50 pg/well (b, d) of microglial lysate as 







Fig. 4 Blinded analysis of CSF samples for misfolded αSyn seeding activity. (a) ThT fluorescence 
showing more αSynagg in PD CSF than in controls. (b) Analysis of PAR showing a higher load of 
αSynagg detected in PD CSF samples [n=15 PD (red) and 11 control (green) CSF samples]. (c) 
Enhanced ThT fluorescence among two PSP samples indicative of αSynagg in CSF of PSP samples. 
(d) Comparison of PAR among PSP and control CSF samples [n=5 PSP (orange) and 5 control 
(green) CSF samples]. All samples were tested in quadruplicates and expressed as the mean of 4 





Fig. 5 Choosing the optimal BH dilution required for the αSyn RT-QuIC assay. Enhanced ThT 
fluorescence of (a) 10-3, (b) 10-4, (c) 10-5, and (d) 10-6 dilutions in the αSyn RT-QuIC assay of PD 









Fig. 6 Testing of misfolded αSyn seeding activity in BH samples from α-synucleinopathy and NS 
cases using the RT-QuIC assay. (a) Enhanced ThT fluorescence in DLB (red, n=5), AD (purple, 
n=10), and control (green, n=8) brain samples, showing more αSynagg in DLB samples. (b) 
Comparison of PAR between the same control, AD and DLB samples showing higher αSynagg load 
in DLB brain samples. (c) Enhanced ThT fluorescence in PD (red, n=11) brain samples compared 
to controls (green, n=11). (d) Comparison of PAR between the same samples showing higher PAR 
in PD relative to controls. Each trace and symbol represent the average of 4 technical replicates. 





Fig. 7 Dot blot analysis of α-synucleinopathy and NS BHs. (a) Dot blot analysis of AD (purple, 
n=10), DLB (red, n=5) and control (green, n=8) BH with αSyn filament conformation-specific (top 
panel) and total αSyn (bottom panel) antibodies. (b, c) Densitometric analyses of (b) αSyn filament 
conformation-specific and (c) total αSyn levels showing that DLB BH has significantly increased 
levels of αSyn filaments compared to AD and control BH, while total αSyn levels did not differ 
among the 3 groups. One outlier was identified and excluded from the control group in (b) using 
the robust regression and outlier (ROUT) detection method with a ROUT coefficient of 1%. (d) 
Dot blot analysis of PD (red, n=5) and control (green, n=5) BH with αSyn filament conformation-
specific (top panel) and total αSyn (bottom panel) antibodies. (e, f) Densitometric analyses of (e) 
αSyn filament conformation-specific and (f) total αSyn levels showing significantly increased 
levels of αSyn filaments for PD compared to control BH, while total αSyn levels did not differ 
between groups.  **p < 0.01, and ***p < 0.001. 
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Table 1. Patient demographic information and Unified Parkinson’s Disease Rating Scale 
(UPDRS) scores at the time of lumbar puncture (F/M, numbers of females/males). 
Subject 
No. 




















5.71 ± 5.44 32.9 ± 26 




1.26 ± 0.88 60.8 ± 
16.48 
3  Controls 
(n=11) 
6/5 62.9 ± 9.24 - - 5.6 ± 6.8 
  
Table 2. Patient demographic information for brain tissue used from the Brain Endowment Bank 
of the University of Miami and UC Davis Alzheimer’s Disease Center (F/M, numbers of 
females/males).  
 
Mean age at death 
(± SD) 
F/M 
University of Miami patients (n)   
Controls (11) 81 ± 7.6 3/8 
Parkinson’s disease (11) 82.5 ± 6.7 1/10 
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Table. 2 continued 
UC Davis Alzheimer’s Disease Center (n)   
Controls (8) 86.25 ± 8.7 4/4 
Dementia with Lewy bodies (5) 83.6 ± 7.7 2/3 
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Objective: This study evaluates the diagnostic potential of detecting pathological α-synuclein 
(paS) in the submandibular gland (SMG) of Parkinson’s disease (PD) patients using an ultra-
sensitive real-time quaking-induced conversion (RT-QuIC) assay. 
Methods: We utilized an ultrasensitive, specific and high-throughput method, the α-synuclein 
(αSyn) RT-QuIC assay to quantify the levels of paS in PD, incidental Lewy body disease (ILBD), 
and control SMG tissues. Immunohistochemically validated SMG samples for p-serine 129 
(pS129) αSyn pathology were tested in the αSyn RT-QuIC assay. 
Results: We determined the quantitative seeding kinetics of paS present in SMG biopsies of 13 
PD, 3 ILBD, and 12 controls with diagnostic cutoffs achieving 100% sensitivity and 94% 
specificity in the αSyn RT-QuIC assay. We also developed a method to determine the seeding 
activity of paS present in SMG formalin-fixed paraffin-embedded (FFPE) sections and tested the 
same population of 13 PD, 3 ILBD, and 16 controls. Interestingly, both PD and ILBD tissues 
showed significantly elevated levels of paS seeding activity compared to controls. End-point 
dilution kinetic analyses revealed that SMG had a wide dynamic range of paS seeding activity. 
Interpretation: Our results are the first to demonstrate the utility of using the RT-QuIC assay on 
peripherally accessible SMG tissues and FFPE tissue sections to detect a PD-related pathological 
process with a high degree of sensitivity and specificity. Additionally, the detection of 3 ILBD 
cases containing immunohistochemically undetected paS demonstrates the αSyn RT-QuIC assay’s 






Parkinson’s disease (PD), Incidental Lewy body disease (ILBD), pathological α-synuclein (paS), 
α-synuclein (αSyn), p-serine 129 (pS129), submandibular gland (SMG), formalin-fixed paraffin-
embedded (FFPE), real-time quaking-induced conversion (RT-QuIC), fast protein liquid 
chromatography (FPLC), , protein aggregation rate (PAR). 
Introduction  
Parkinson’s disease (PD) is the most common movement disorder, affecting predominantly the 
elderly population over the age of 60 years.  Genetically linked forms of PD are known to have an 
early onset. The prevalence, mortality, and disability-adjusted life-years of PD have doubled in the 
past decade and will continue to increase in the near future.1 The current state-of-the-art diagnosis 
of PD essentially relies on the clinical signs judged by a clinician2 and may be further augmented 
by functional dopaminergic imaging of the basal ganglia.3 However, by the time of onset of 
clinically diagnostic symptoms, about 75% of striatal dopaminergic terminals and 50% of cell 
bodies in the substantia nigra have been lost.4 The lack of reliable diagnostic markers for the early 
detection of PD has been a challenge in clinical neurology. Retrospective studies have revealed no 
improvement in the accuracy of clinical PD diagnosis, especially in its early stages, over the past 
two decades.5 The accumulation of misfolded pathological α-synuclein (paS) in brainstem, limbic, 
and cortical structures remains the major histopathological hallmark for confirming the diagnosis 
of PD.6 The discovery of peripheral biomarkers that aid in the earlier detection of PD-related 
pathological processes would substantially improve clinical diagnostic accuracy, subject selection 
for clinical trials, assessment of target engagement, and the monitoring of disease progression 
and/or response to therapy.7-9 Considerable effort has been made to develop biomarkers, such as 
Syn protein, in patient samples that can be used as diagnostic tools, especially in the early stage 
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of the disease. Recently, our group10-14 and others15-17 established an ultrasensitive protein seeding 
assay called real-time quaking-induced conversion (RT-QuIC) to quantify multiple disease-
specific misfolded proteins, including Syn and prions, in clinical samples. The αSyn RT-QuIC 
assay has detected paS in CSF and brain homogenate samples from PD and dementia with Lewy 
body (DLB) subjects with high sensitivity and specificity. Further advantages of this method 
include identification of different -synucleinopathy strains and diagnostic applications from other 
tissues in prion disease.10, 17 With these advancements in improved detection of paS in biofluids, 
it may now be plausibly applied to peripherally biopsied tissues.18-20 In the current study, we 
evaluated the diagnostic potential of paS present in the readily accessible submandibular gland 
(SMG) using this ultra-sensitive αSyn RT-QuIC assay. Beach et al.21-25 recently reported the 
presence of paS in the SMG by immunohistochemical staining for pS129 αSyn on slide-mounted, 
formalin-fixed paraffin-embedded (FFPE) SMG sections from both human autopsies and needle 
biopsies in live patients. Therefore, we hypothesized that human SMG is a suitable test material to 
detect paS using the αSyn RT-QuIC assay. To achieve this goal, we optimized the RT-QuIC assay 
to analyze autopsied SMG tissues and, and most importantly, FFPE SMG tissue sections, and were 
able to differentiate PD, ILBD, and control subjects. Overall, we provide the first evidence for the 
potential of SMG αSyn RT-QuIC as a sensitive, objective and quantitative assay for a PD-related 
pathological process. 
Methods 
Processing of SMG tissues and FFPE sections 
Frozen SMG tissues and slide-mounted FFPE tissue sections were provided by the Banner Sun 
Health Research Institute (BSHRI; Phoenix, AZ). Subjects were recruited and clinically followed 
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to autopsy and neuropathological examination as part of the Arizona Study of Aging and 
Neurodegenerative Disorders/Brain and Body Donation Program 
(www.brainandbodydonationprogram.org).26, 27 All cases were neuropathologically examined 
using specific diagnostic criteria for PD.28 Cases with Lewy bodies but not meeting the diagnostic 
criteria for PD were considered as ILBD. Controls consisted of normal elderly subjects or patients 
with Alzheimer’s disease (AD) without Lewy body pathology. Our study utilized SMG tissues 
from 13 PD, 3 ILBD, and 12 control subjects and SMG FFPE sections from matching subjects and 
an additional 4 controls. The details of samples and patient history are presented in Table 1. All 
subjects had been clinically and neuropathologically characterized based on previously published 
criteria.26, 29 Frozen tissue was collected fresh, kept frozen at -80 oC, then shipped on dry ice and 
stored again at -80 oC until tested in the αSyn RT-QuIC assay. SMG tissue homogenates (10% 
w/v) were prepared in sterile phosphate-buffered saline (PBS) using a Bullet Blender (Next 
Advance) with 0.5-mm zirconium oxide beads for 2 min at maximum speed and 4 oC. The 10% 
homogenates were then used to make various dilutions ranging from 10-2 to 10-8 with sterile PBS. 
For FFPE sections, paraffin-embedded SMG sections (6-µm thick) from the same autopsy cases 
were mounted onto electrostatically charged glass slides and shipped to Iowa State University. To 
recover slide-mounted FFPE SMG sections, we washed the slides twice in 100% xylene for 10 
min each. After the xylene washes, slides were submersed for 10 minutes each in a descending 
series of alcohol dilutions (100%, 95%, and 70%) to rehydrate the tissues. Next, the slides were 
washed with sterile PBS as a final step. After washing, SMG tissue sections were scraped off from 
slides and then weighed. From this point, they were used as a regular tissue homogenate in the 




Brain homogenate preparation 
Post-mortem human brain samples used for the end-point dilution analysis were provided by the 
University of Miami Brain Endowment Bank of the NIH NeuroBioBank. Substantia nigral tissues 
from pathologically confirmed PD cases were used to make 10% w/v homogenates in sterile PBS 
using a Bullet Blender with 0.5-mm Zirconium oxide beads for 2 min at maximum speed. The 
10% homogenates were used to make dilutions ranging from 10-2 to 10-7 using PBS and tested in 
the αSyn RT-QuIC assay as shown in Fig 4.  
Purification of recombinant human αSyn protein by fast protein liquid chromatography 
(FPLC) 
Purification of recombinant human WT αSyn was performed as described in our recent 
publication.10 In brief, E. coli Rosetta DE2 cells were transformed with a human WT αSyn-
expressing plasmid and plated on LB agar containing kanamycin (50 µg/mL). Single colonies from 
this culture were individually inoculated into tubes containing 5 mL LB media supplemented with 
kanamycin. The mini-cultures were grown overnight in an incubator at 225 rpm and 37 oC and 
expanded to 1 L cultures. When the bacterial cultures reached an OD600 of 0.7, 1 mM IPTG was 
added to induce αSyn expression, and after 4.5 h, cultures were harvested by pelleting at 4200 x g 
for 20 min at 4 oC. Later, bacterial pellets were lysed by adding 10 mL of 50 mM Tris and 500 
mM NaCl at pH 7.4 using an Omni tissue homogenizer and then heat-precipitated at 85 oC for 15 
min. The tubes were cooled on ice and all the subsequent steps were carried out at 4 oC. The 
precipitates were removed by centrifugation at 15,000 x g for 20 min at 4 oC and DNA was 
precipitated out of the supernatants by incubating with streptomycin (10 mg/mL) for 30 min. The 
resulting solutions were centrifuged at 23,000 x g for 30 min, and the supernatants were diluted 
10-fold and dialyzed using a 3-kDa molecular weight cut-off (MWCO) snakeskin dialysis tubing 
165 
 
in a 20 mM Tris HCl buffer at pH 8 overnight at 4 oC. On the following morning, the dialyzed 
supernatants were concentrated and 0.2-µm filtered before loading onto a Sephacryl 200 column 
(GE Healthcare Life Sciences) for size-exclusion FPLC. The column was pre-equilibrated in 20 
mM Tris-HCl buffer of pH 8 at 4 oC. Fractions having recombinant αSyn were determined based 
on Coomassie staining of the peak fractions. The fractions positive for recombinant αSyn were 
combined, concentrated, and 0.2-µm filtered before loading onto a HiPrep Q FF 16/10 anion-
exchange column. After injecting into FPLC, a wash step was performed using 50 mM NaCl for 
5 column volumes followed with a linear gradient in 10 column volumes up to 1 M NaCl in 20 
mM Tris, pH 8, and αSyn protein was recovered between 300 and 350 mM NaCl. The peak 
fractions were collected and analyzed through polyacrylamide gel electrophoresis followed by 
Coomassie staining to visualize the protein fractions. Fractions having protein were pooled and 
dialyzed overnight in 20 mM Tris, pH 8, at 4 oC. On the next day, the buffer was replaced with a 
new buffer for one hour and the protein was 0.2-µm filtered. Protein concentrations were estimated 
using a NanoDrop spectrophotometer with an extinction coefficient of 0.5960 mg∙mL− 1∙cm− 1. The 
protein was lyophilized in aliquots with a final concentration of 1 mg/mL and stored at -80 oC until 
use.  
Polyacrylamide gel electrophoresis 
Protein fractions from size-exclusion or anion-exchange chromatography were mixed with an 
equal volume of 2X sample-loading buffer (2X Laemmli sample buffer, Bio-Rad) with 2-
mercaptoethanol, vortexed, and then boiled for 5 min. Proteins were separated by polyacrylamide 
gel electrophoresis using 4-20% gradient gels (Bio-Rad) followed by staining with Coomassie blue 
and destaining.  
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Determining the purity and activity of recombinant αSyn protein as a suitable RT-QuIC 
substrate  
The purity of monomeric recombinant αSyn was confirmed by Coomassie stain. Additionally, we 
compared the thioflavin T (ThT) fluorescence intensity between monomeric recombinant αSyn 
versus aggregated αSyn (αSynagg) as described in our recent publication.
10  Briefly, 95 µL of 25 
µM ThT was added to a 384-well plate with 2.5 µL of monomeric recombinant αSyn or αSynagg 
and incubated at room temperature for 2 min. Fluorescence readings were taken at excitation and 
emission wavelengths of 450 and 480 nm, respectively. We noticed an enhanced ThT fluorescence 
>80-fold with αSynagg compared to monomeric recombinant αSyn. 
αSyn RT-QuIC assay 
The αSyn RT-QuIC assay was performed as described previously10-14, 30 using a 96-well clear-
bottom plate (Nalgene Nunc International). For all the αSyn RT-QuIC assays, the reaction mixture 
consisted of final concentrations of 40 mM phosphate buffer (pH 8.0), 170 mM NaCl, 10 µM ThT, 
0.00125% sodium dodecyl sulfate (SDS) and 0.1 mg/mL of recombinant αSyn. Prior to each 
reaction setup, the recombinant αSyn was filtered through a 100-kDa MWCO filter to retain 
monomer filtrate. After optimizing the RT-QuIC assay test conditions for the SMG tissue 
homogenates, we tested the remaining samples using these conditions. Next, as a test validation, 
we performed blind testing of all the same samples in the αSyn RT-QuIC assay. To seed the RT-
QuIC reactions, a 10-4 % w/v dilution of SMG tissue homogenates or a 10-2 % w/v dilution for 
FFPE tissue sections was used. Samples were homogenized to 10% w/v and diluted 10-fold with 
sterile PBS as described previously.10-14 Each reaction consisted of 5 µL of test sample as seed and 
95 µL of αSyn RT-QuIC reaction mixture per well of a 96-well plate preloaded with 6 0.8-mm 
silica beads (OPS Diagnostics) per well. Next, the plates were sealed with a plate sealer (Nalgene 
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Nunc International) and reactions were initiated in a CLARIOstar (BMG) plate reader with 
alternating 1-min shake and rest cycles (double orbital, 400 rpm) at 42 oC. ThT fluorescence 
readings were recorded at excitation and emission wavelengths of 450 and 480 nm, respectively, 
every 30 min over a period of either 24 h for frozen samples or 60 h for FFPE tissue sections. 
Samples were run in quadruplicates and considered positive when at least two wells crossed the 
threshold fluorescence, defined as the average fluorescence of the first 10 cycles for all samples 
plus 10 standard deviations. The protein aggregation rate (PAR) for each sample was calculated 
by taking the inverse of the time required to cross the threshold fluorescence.  
Statistical analysis 
GraphPad 7.0 was used for statistical analysis. Raw data were analyzed using Student’s unpaired 
t-test for comparing two groups and one-way ANOVA for comparing more than two groups. 
Asterisks were assigned as follows: *p ≤ 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. The 
number of biological replicates is expressed as “n” unless otherwise mentioned. JMP statistical 
software was used for multivariate comparisons. 
Results 
Determination of optimal test conditions for the SMG αSyn RT-QuIC assay 
We10-14 and others31 have previously shown that an optimal concentration of SDS in the reaction 
mixture is critical for the sensitivity of the RT-QuIC assay. Therefore, we first optimized the SDS 
concentration to detect paS seeding activity in the SMG RT-QuIC assay. We tested SMG tissue 
homogenates prepared from PD and control (n=6 each) cases in the αSyn RT-QuIC assay with and 
without SDS. We observed an increase in ThT fluorescence and protein aggregation rate (PAR) as 
determined based on the inverse of time to cross the threshold fluorescence, with 0.00125% SDS 
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(Fig 1A & 1B) compared to the reactions seeded without SDS in the reaction mixture (Fig 1C & 
1D). Well scan pattern displayed a greater deposition of paS amyloids in a PD sample compared 
to control SMG sample (Fig. 1E). Reactions without SDS exhibited delayed RT-QuIC 
amplification with substantially increased lag periods. Thus, the 0.00125% SDS was determined 
to be a rate-limiting factor for efficient amplification of paS in the SMG αSyn RT-QuIC assay. 
Next, using the optimized reaction conditions, we assessed the reproducibility of RT-QuIC by 
repeating the experiment three times. The repeated assay results were identical, suggesting a high 
reproducibility for αSyn RT-QuIC to determine the seeding activity of SMG paS.  
Rapid detection of paS seeding activity in SMG tissues  
After establishing the optimal SDS concentration in the SMG RT-QuIC assay, we tested the paS 
seeding activity of frozen SMG tissues collected from 13 PD, 3 ILBD, and 12 age-matched control 
subjects. The SMG homogenates from PD cases rapidly seeded the reactions, crossing the 
threshold fluorescence within 7 h, whereas paS seeding activity in ILBD tissue homogenates 
needed 20 h. In contrast, paS seeding activity in SMG tissue homogenates from controls did not 
occur during the 24-h period (Fig 2A). Similarly, SMG tissue homogenates from PD and ILBD 
samples exhibited significantly higher PARs when compared with the age-matched control 
samples (Fig 2B). When we blindly tested all the SMG homogenates, results remained unchanged, 
thereby further enhancing the rigor of the αSyn RT-QuIC assay. Collectively, these results 
demonstrate that RT-QuIC determination of paS seeding activity and PAR may be used to 
effectively discriminate PD, ILBD, and control samples. Also, the blind study design confirms the 




Detection of paS seeding activity in FFPE sections of SMG tissues  
Next, we sought to determine whether the αSyn RT-QuIC assay can be adopted for detecting paS 
in slide-mounted FFPE autopsied SMG tissue sections (6-µm thick) obtained from the same 
population of immunohistologically confirmed PD (n=13), ILBD (n=3), and control (n=16) 
subjects. The FFPE sections of autopsied SMG tissues were processed for RT-QuIC as described 
in the Methods. Remarkably, our RT-QuIC results showed that the SMG FFPE section-derived 
homogenates from PD cases rapidly seeded the reactions within 10 h, as determined by the time 
to cross the threshold fluorescence (Fig 3A). While the 3 ILBD FFPE sections required 30-40 h to 
cross the threshold fluorescence, control FFPE sections did not show any threshold fluorescence 
up to 40 h (Fig. 3A). As such, SMG FFPE sections from PD samples exhibited a significantly 
higher PAR than both ILBD and age-matched control samples (Fig 3B). Overall, these results 
clearly demonstrate the potential diagnostic utility of the αSyn RT-QuIC assay on peripherally 
accessible SMG biopsy tissue specimens from histological slides.   
Quantitative assessment of paS seeding activity in SMG and brain tissues from PD cases  
We further compared SMG and brain tissue homogenates from confirmed PD cases in an end-
point dilution analysis to determine the relative seeding activity of paS from the two tissues. 
Spearman-Kärber analyses were performed to determine the seeding-competent dilutions based on 
the percentage of the RT-QuIC reactions that turn positive in each dilution tested. This analysis 
provides an estimation of the median seeding dose (SD50) representing the seeding concentration 
at which 50% of the replicates turn positive in the RT-QuIC assay. For brain tissues, we tested log-
fold dilutions from 10-3 to 10-7 in quadruplicates (Fig 4A). Positive reactions were observed in all 
four replicates of 10-3 and 10-4, in two for 10-5, and one replicate amplified at 10-6. None of the 
replicates amplified in the 10-7 dilution. For SMG tissues, we tested two samples with log-fold 
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dilutions from 10-2 to 10-8 in quadruplicates in the αSyn RT-QuIC assay. All four replicates (100%) 
of the two SMG cases exhibited positive reactions in dilutions ranging from 10-2 to 10-5, while 
75% and 25% of the replicates showed positive reactions in 10-6 and 10-7, respectively (Fig 4B). 
None of the replicates amplified in the 10-8 dilution. Brain homogenate and SMG tissues showed 
SD50 titers of 8.8x10
8 and 2x106 per mg of tissue, respectively. These robust results support SMG 
tissue as an efficient seeding material whose high dynamic range on the αSyn RT-QuIC assay 
approaches that of brain homogenates, albeit with differences in the RT-QuIC reaction mixture 
composition in both types of samples. Collectively, these results further reveal that SMG biopsy 
tissues of PD patients harbor misfolded αSyn with high seeding activity.   
Discussion 
Developing a reliable test for PD-related pathology has been very challenging due to individual 
variation in the progression and severity of the diseases. Recent developments in protein 
misfolding assays, such as RT-QuIC and protein misfolding cyclic amplification (PMCA), have 
made the rapid and quantitative detection of misfolded proteins in biological samples possible.11, 
12, 32-34 RT-QuIC was first established as a diagnostic tool for prion diseases due to its ultra-
sensitive detection of prions from a variety of samples10-12, 14, 35. Since αSyn shares an aggregation 
mechanism similar to prion propagation, misfolding techniques such as PMCA and RT-QuIC have 
been used to detect paS in brain and CSF from patients affected by synucleinopathies.10, 15, 36-38 
CSF sampling is more invasive and can potentially invoke headaches and back pain and it risks 
continued CSF leakage and infection.39 Therefore, utilizing more peripherally biopsied tissues may 
be a preferable strategy.  In this regard, Beach and colleagues examined tissue sections from 
autopsied PD patients and demonstrated that the SMG, which embeds components of the 
peripheral nervous system, exhibited significantly higher pS129 αSyn immunoreactivity compared 
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to age-matched control sections.25, 40 Therefore, immunohistochemical detection of pS129 αSyn in 
autopsied and biopsied SMGs has since been shown to be a highly specific biomarker assay of PD 
and dementia with Lewy bodies.21, 24 22, 23 However, current immunohistochemical methods for 
specific detection of paS require pathology expertise to accurately interpret the slides and may 
have inherently lower sensitivity as compared to RT-QuIC assays. 
To address the potential gaps in biomarker-based diagnostic approaches, we adopted an αSyn RT-
QuIC assay to detect the seeding activity associated with paS from the SMG tissues of autopsied 
PD patients. In this study, we demonstrate paS seeding activity from both frozen and FFPE SMG 
sections of PD and ILBD patients. In addition, we characterized the seeding kinetics of paS by 
applying the current gold standard approach, confirming paS using histopathology. Overall, these 
results demonstrate that RT-QuIC-based seeding activity may now be extended to testing larger 
cohort sets of both frozen tissues and FFPE sections of SMG since it was able to discriminate PD 
and ILBD subjects from age-matched controls with 100% sensitivity and 94% specificity. These 
findings have important implications for developing an RT-QuIC assay on SMG biopsy tissues 
from live patients.22 In contrast to the 100% sensitivity achieved with SMG RT-QuIC, its less than 
100% specificity might be due to both the age and AD-related pathology of the control subjects.41 
Despite detecting paS seeding activity, one limitation associated with the collection of SMG 
biopsies is an insufficient amount of glandular tissue in the biopsied sample, which can be 
overcome by using a larger needle size.22, 23 However, this may not be a major limitation given the 
RT-QuIC’s ability to detect miniscule protein concentrations. Another limitation is that the SMG 
biopsy procedure is invasive and although rare, complications such as hematoma, infection, and 
facial nerve damage have been documented.42 These risks are also minimized when using fine-
needle biopsy in contrast to the core-needle biopsy method. A schematic representation of the 
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scope of this assay as a potential biomarker for PD and the key steps involved in sample collection 
and testing are depicted in Fig 5. Moreover, the associations of RT-QuIC PAR values with age, 
sex, MMSE scores, post-mortem interval, Braak stages, and the amount of pathological α-
synuclein were assessed using multivariate regression analysis. In control, ILBD, and PD cases, 
no effect of sex (p=0.5681), age (p=0.2809), MMSE scores (p=0.2142), Braak staging (p=0.5668), 
or post-mortem time (p=0.4876) was observed on RT-QuIC assay results. Only pathological 
discrimination of PD from control and the amount of paS based on unified LB staging differed 
significantly (p<0.0001) with RT-QuIC PAR values (Table 2). Altogether, our results demonstrate 
that the ultrasensitive RT-QuIC assay can be readily employed for detection of paS in SMG biopsy 
samples, enabling an easy, relatively less-invasive approach for molecular diagnosis of PD and 
potentially other related synucleinopathies. Although the αSyn RT-QuIC assay has previously 
been shown to differentiate the strains in synucleinopathy cases using brain tissue17, the use of 
SMG αSyn RT-QuIC for the differential diagnosis of other Parkinsonism-related disorders such 
as DLB, MSA, and PDD as well as other αSyn strain typing remains to be explored. Future 
prospective studies are warranted to test the performance of the assay in clinical settings.  
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Figure 1. Optimization of the αSyn RT-QuIC assay for SMG homogenates. 
(A, B) Testing of SMG samples in the αSyn RT-QuIC assay using 0.00125% SDS in the RT-QuIC 
reaction mixture. PD samples showed enhanced ThT fluorescence (A) and higher PAR (B) 
compared to control samples. (C, D) Testing of SMG samples in the αSyn RT-QuIC assay without 
SDS in the RT-QuIC reaction mixture. The lag period for enhanced ThT fluorescence increased in 
PD cases compared to controls (C), and no significant differences in PAR were observed between 
controls and PD (D). (E) Well-scan image of control and PD SMG samples showing deposition of 
protein aggregates in a PD sample in response to shake and rest cycles (red color) of the plate 
reader compared to a control (grey color). Each symbol represents the average of 4 technical 
replicates. A total of 6 PD and 6 controls were tested in the αSyn RT-QuIC assay and expressed 




Figure 2. Reproducible detection of paS seeding activity in SMG homogenates. 
(A) ThT fluorescence in PD, ILBD, and control SMG homogenates, showing more paS in PD and 
ILBD samples. (B) Comparison of PAR between the PD, ILBD, and control SMG homogenate 
samples showing higher paS load in PD and ILBD. We tested 13 PD (red), 3 ILBD (orange), and 
12 control (green) samples in the αSyn RT-QuIC assay. All samples were tested in quadruplicates 




Figure 3. Detection of paS seeding activity in SMG FFPE sections. 
(A)  ThT fluorescence in PD, ILBD, and control SMG homogenates, showing more paS in PD and 
ILBD samples. (B) Comparison of PAR between the PD, ILBD, and control samples showing 
higher paS load in PD than in ILBD and control SMG homogenates. No statistical significance 
was observed between the ILBD and control SMG homogenates. We tested 13 PD (red), 3 ILBD 
(orange), and 16 control (green) samples in the αSyn RT-QuIC assay. All samples were tested in 









Figure 4. Determination of median seeding dose (SD50) of paS in PD samples using the αSyn RT-
QuIC assay.  
End-point dilutions of PD brain homogenates (A) and SMG tissue samples (B) by αSyn RT-QuIC. 
Each trace represents the average of 4 replicates. Tables to the right of each graph indicate the 
concentration of SD50 units calculated by Spearman-Kärber analysis representing one brain 









Figure 5. Schematic representation of the αSyn RT-QuIC assay as a tool for monitoring PD using 
SMG biopsy.  
SMG tissue sampled using needle biopsies is processed for testing in the RT-QuIC assay to assist 
in clinical practice. The RT-QuIC workflow runs in a high-throughput format using a 96-well 
plate. Each well consists of 5 µL of SMG homogenate as a seed and 95 µL of αSyn RT-QuIC 
reaction mixture containing recombinant human αSyn protein as a substrate. During the reaction 
process, the samples with paS show higher ThT fluorescence compared to controls, and the 
reactions can be monitored in real-time with final data processing being completed in a 24-48 h 
window for visualization and reporting. The SMG αSyn RT-QuIC assay may find clinical 




Table 1. Patient demographic information with unified Lewy body (LB) staging, mini mental state 
examination (MMSE) scores, Braak staging, RT-QuIC PAR values, and pathological diagnosis for 
SMG tissues used from the BSHRI. Samples lacking enough LB pathology to confirm as PD were 
classified under ILBD (M: male; F: female; PMI: post-mortem interval in hours; PAR: protein 
aggregation rate). (Unified LB stages 0: No LB; I: Olfactory Bulb only; IIa: Brainstem 



















1 10-22 F 59 3.15 0 0 NA III Control 
2 11-
102 
M 93 2.08 0 0 25 I Control 
3 12-41 M 97 2.5 0 0 29 II Control 
4 13-49 F 75 2.5 0 0.05 28 I Control 
5 14-19 F 90 2.5 0 0 30 IV Control 
6 14-42 M 92 2.3 0 0 28 IV Control 
7 9-57 M 80 3.5 0 0 NA II Control 
8 13-40 M 73 4.12 0 0 NA II Control 
9 16-10 M 83 4.25 0 0 29 IV Control 
10 16-32 M 79 4.3 0 0 28 III Control 




Table 1 continued 
12 10-70 M 74 3.25 0 0 NA II Control 
13 14-36 F 82 3.17 0 0 29 III Control 
14 14-47 F 77 2.63 0 0 27 II Control 
15 15-08 M 78 3.25 0 0 28 II Control 
16 14-20 F 93 2.33 0 0 28 I Control 
17 11-05 M 81 2.25 I 0.04 30 IV Incidental 
Lewy body 
disease 
18 11-28 F 79 2.22 I 0.05 30 III Incidental 
Lewy body 
disease 





F 92 3.67 IIb 0.05 27 III Parkinson’s 
disease 
21 12-29 M 86 3 IV 0.05 17 III Parkinson’s 
disease 
22 12-42 M 69 3.37 IV 0.11 24 II Parkinson’s 
disease 




24 13-11 M 81 3.62 III 0.13 NA III Parkinson’s 
disease 
25 13-17 M 83 3 IIa 0.14 29 IV Parkinson’s 
disease 
26 13-18 M 79 3.25 IIa 0.12 29 IV Parkinson’s 
disease 
27 16-02 M 89 2.4 IV 0.08 15 IV Parkinson’s 
disease 
28 16-37 M 70 3.9 IV 0.08 NA II Parkinson’s 
disease 
29 16-39 M 70 4.12 IV 0.08 13 IV Parkinson’s 
disease 
30 16-47 M 83 2.47 IV 0.08 15 IV Parkinson’s 
disease 
31 15-84 M 81 2.38 IV 0.07 26 IV Parkinson’s 
disease 







 Table 2 Analysis of the effect of pathological diagnosis, sex, age, MMSE score, Braak staging, 
and the amount of pathological α-synuclein on results of the RT-QuIC assay. In control, ILBD, 
and PD cases, no effect of sex (p=0.8681), age (p=0.2809), MMSE score (p=0.2142), or Braak 
staging (p=0.5668) was observed on RT-QuIC assay results. Only pathological diagnosis and the 
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GENERAL CONCLUSION AND FUTURE DIRECTIONS 
In this section, I present a general overview of the results from each chapter and show how they 
fit in the overall scope of biomarker discovery. We developed an ultrasensitive, real-time quaking-
induced conversion (RT-QuIC) assay to detect the misfolded proteins associated with 
proteinopathies such as prionopathies and synucleinopathies (Fig. 1). We used the RT-QuIC assay 
to understand the biomarker role of various aggregated proteins such as misfolded prions and 
αSyn. Specific findings are covered under the ‘Results’ section and their implications can be found 
in the ‘Discussion’ section of the pertinent chapter. 
Chapter I introduced the proteinopathies including prionopathies, synucleinopathies, and 
tauopathies with the main emphasis on chronic wasting disease (CWD), Parkinson’s disease (PD), 
and improving their early diagnosis. We also reviewed current knowledge on the role of Mn in 
proteinopathies, especially its interaction with prion and αSyn proteins.  




In chapter II, we provide a sensitive misfolded prion detection and quantification platform using 
rectum-associated mucosal lymphoid tissue (RAMALT) from elk. Since CWD is a disease with a 
very long incubation period, a robust antemortem test for early diagnosis is essential for healthy 
herd management. In elk, abnormal prions accumulate in the brain and in lymph nodes of the head, 
from where they spread to peripheral lymphoid tissues like RAMALT (Sigurdson and Aguzzi 
2007). Hence, we evaluated the RT-QuIC assay to detect CWD using RAMALT samples by 
comparing its results with a confirmatory diagnostic test such as IHC of RAMALT, obex, and 
MRPLN in a blinded manner. We noticed that animals with MM polymorphism at codon 132 were 
more positive compared to the ML genotype and correlated well with the IHC of RAMALT 
samples. Therefore, the RT-QuIC assay has the potential to be a useful and complementary 
diagnostic tool for the antemortem diagnosis of CWD using RAMALT samples.  
In Chapter III, we established the sensitive RT-QuIC assay for cell culture models of prions and 
tested the role of Mn in the templated conversion of prion protein. We also tested the role of other 
metals like Cu, Mg, and Ni in the templated conversion of recombinant prion protein, but none of 
these metals caused increased prion aggregation like Mn. Our cell culture-coupled RT-QuIC assay 
can screen many anti-prion compounds, thereby improving the translational impact of targeted 
therapeutics. Furthermore, cell culture-coupled RT-QuIC can be adapted to other prionopathies 
that conform to the principle of template-driven conversion of monomers into aggregates to 
produce pathogenicity like in Parkinson’s, Alzheimer’s, and other protein-misfolding diseases. 
In Chapter IV, we investigated the role of Mn exposure in αSyn aggregation. In humans, one of 
the routes leading to chronic overexposure to Mn is the inhalation of Mn-rich fumes or dust in 
occupations like welding and mining.  The inhaled Mn not only reaches the lungs, but also crosses 
the blood-brain barrier intranasally via the olfactory neuroepithelium. Thus, Mn can enter the brain 
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directly in high-risk groups, such as welders and miners, and cause a Parkinsonian syndrome. It is 
also known that exposure to Mn can exacerbate neurotoxicity by increasing exosome release in 
cell culture and animal models. Hence, we used the RT-QuIC assay to detect αSyn aggregates 
associated with exosomes isolated from the serum and plasma of humans occupationally exposed 
to welding fumes and healthy controls. Furthermore, we identified several non-coding RNAs and 
pathways associated with the serum exosomes through RNA sequencing analysis. RT-QuIC assay 
was not only able to detect the exosomal αSyn aggregates from the welder samples, but also 
detected the αSyn aggregates associated with exosomes isolated from mouse dopaminergic cells 
treated with Mn, suggesting the potential role of Mn in promoting αSyn aggregation.               
Next, in Chapter V, we evaluated the potential use of RT-QuIC for diagnosing synucleinopathies. 
The accumulation of αSyn aggregates in the brain is the main pathological event in 
synucleinopathies like PD, dementia with Lewy bodies (DLB), and multiple system atrophy 
(MSA). Early and accurate diagnosis of these disorders has been hampered by the lack of a well-
characterized, sensitive diagnostic assay, thereby resulting in ineffective treatment strategies and 
delayed counseling of patients and their families. A definitive diagnosis has been possible only by 
post-mortem evaluation using immunohistochemistry (Braak and Braak 2000; Holdorff 2006). 
Thus far, no in vivo biomarkers are approved to differentiate between these clinically similar 
syndromes, however, detection of αSyn aggregates as a diagnostic biomarker offers a promising 
approach.  Hence, we exploited the ability of the αSyn RT-QuIC assay to measure αSyn aggregates 
levels in human CSF samples. We achieved 100% sensitivity and specificity with a blinded 
analysis of a subset of CSF samples. Based on results using brain homogenates (BHs), we were 
able to differentiate α-synucleinopathy (DLB and PD patients) from controls with 94% sensitivity 
and 100% specificity. Overall, the RT-QuIC assay can be used to detect αSyn aggregates 
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associated with CSF and brain tissues, and it can be readily adopted to other easily accessible 
biofluids such as plasma and serum samples. 
In Chapter VI, we extended the use of the RT-QuIC assay to detect αSyn aggregates associated 
with the submandibular gland (SMG) tissues of PD patients. We already established the RT-QuIC 
assay for CSF samples, however, the procedure associated with CSF collection is more invasive 
and potentially associated with side effects such as headaches, back pain, and infection. Utilizing 
more peripheral biopsied tissues may be a preferable strategy.  Toward this end, Beach et al. 
recently demonstrated that SMG sections from autopsied PD patients have significantly higher 
phosphorylated serine 129 (pS129) αSyn immunoreactivity compared to age-matched control 
sections; the SMG embeds part of the peripheral nervous system (Beach et al. 2010; Del Tredici 
et al. 2010). Therefore, immunohistochemical detection of pS129 αSyn in autopsied and biopsied 
SMG tissues has been shown to be a highly specific biomarker assay of PD and dementia with 
Lewy bodies (Beach et al. 2013; Beach et al. 2016) (Adler et al. 2017; Adler et al. 2014). However, 
current immunohistochemical methods for specific detection of pathological αSyn (paS) require 
pathology experts to accurately interpret the slides. Also, immunohistological tests may have 
inherently lower sensitivity compared to RT-QuIC. To address such potential gaps in diagnostic 
assessment, we adopted an RT-QuIC assay to detect the seeding activity associated with paS from 
the SMG tissues of PD patients collected during autopsy. We first used frozen samples of SMG 
tissue to optimize the test conditions of the αSyn RT-QuIC assay. Next, we tested a small set of 
frozen SMG tissues for quantitative detection of paS and were able to differentiate PD from control 
subjects with high confidence. In addition, to optimize the paS seeding activity in frozen tissues, 
we also developed and optimized the RT-QuIC assay to detect paS present in formalin-fixed 
paraffin-embedded (FFPE) SMG sections from PD patients, providing the possibility of 
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confirming paS in histological sections from autopsied or biopsied subjects with PD and other 
synucleinopathies. Our blinded analysis also confirmed the reproducibility of the assay.  Overall, 
adopting the SMG RT-QuIC assay can greatly improve diagnostic accuracy as this assay was able 
to discriminate PD subjects from age-matched controls with 100% sensitivity and 94% specificity.  
Collectively, RT-QuIC is a highly sensitive and specific assay that can be easily tailored to detect 
low levels of protein aggregates present in a variety of antemortem samples from patients affected 
by proteinopathies. 
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